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AC  Anterior chamber
ACD  Anterior chamber depth
AL  Axial length
ALPI  Argon laser peripheral iridoplasty
BAC  Benzalkonium chloride
BCVA  Best corrected visual acuity
BP  Blood pressure
BSS  Balanced salt solution
DS  Deep sclerectomy
DSCI  Deep sclerectomy with collagen implant
EXG  Exfoliation glaucoma
EXS  Exfoliation syndrome
GP  Goniopuncture
HRT  Heidelberg Retina tomograph
IOP  Intraocular pressure
LOXL1  Lysyl oxidase-like
MIGS  Minimally invasive glaucoma surgery
MMC  Mitomycin-C
NTG  Normal tension glaucoma
OCT  Optical coherence tomography
ONH  Optic nerve head
POAG  Primary open-angle glaucoma
SD  Standard deviation
SLT  Selective lasertrabeculoplasty
TDM  Trabeculo-Descemet’s membrane
UBM  Ultrasound biomicroscopy
YAG  neodymium-doped yttrium aluminum garnet
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ABSTRACT
This study was undertaken to determine outcome of deep sclerectomy (DS) with and 
without mitomycin C (MMC), especially in patients with normal tension glaucoma 
(NTG). DS has been a method for treating eyes suffering from glaucoma for many 
years, but the intraocular pressure (IOP) lowering effect of DS to NTG eyes with 
low preoperative IOP has not been studied previously. MMC is widely used in 
glaucoma surgery. When aiming for low postoperative IOP, however, MMC may 
introduce postoperative adverse effects on operated eyes. Although the majority 
of glaucoma patients scheduled for surgery have primary open-angle glaucoma 
(POAG), exfoliation glaucoma (EXG) is common in Nordic countries. The number 
of DS studies on EXG eyes is limited, and the number of eyes in these studies 
has been low. IOP lowering with DS results in a decrease in best corrected visual 
acuity (BCVA) during the first postoperative weeks, the reasons for which are not 
thoroughly known.
The aims of this thesis were to investigate 1) the effect of DS in NTG eyes, 2) 
the possible additional IOP-lowering effect and adverse effects of MMC use, 3) the 
effect of DS in POAG and EXG eyes and 4) changes to BCVA, and anterior and 
posterior structures of the eye after DS.
DS reduced IOP efficiently in NTG eyes, an effect that could be noticed 
throughout our follow-up: postoperative IOP with and without MMC was 9 to 10 
mmHg respectively, after 6 to 9 years of follow-up. 
Hypotony was more common during the first postoperative months when MMC 
was used. In the MMC group, IOP was lower until 5 years postoperatively; after that, 
no difference was evident in IOP. Goniopuncture (GP) was common in both groups. 
In the MMC group 87%, and the non-MMC group 100% of eyes needed GP during 
follow-up. Needling was needed in 16 of 34 eyes and tended to be repeated more 
often in the non-MMC group. Four eyes lost two or more lines of best-corrected 
visual acuity (BCVA). The rate of serious postoperative complications was low.
DS also lowered IOP efficiently in POAG and EXG eyes. Mean postoperative 
IOP was 16.8 mmHg in POAG, and 16.5 mmHg in EXG after 3 years´ follow-up. 
That GP and re-operations were more common in EXG may indicate a stronger 
fibrotic response or altered function of the Descemet’s membrane in these eyes. 
Studying possible variables to explain surgical success with the Cox regression 
model revealed that an IOP of 2 to 14 mmHg one week postoperatively indicated 
a lower rate of losing surgical success. 
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BCVA decreased when IOP was lowered with DS, but had returned to its 
preoperative level 4 weeks postoperatively. Axial length was shortened by 0.1 
mm, and a steeper corneal meridian changed from 44.6 to 44.9 D. Thickness of 
the central cornea decreased 6 μm when measured with Scheimpflug. Changes in 
macular structures in optical coherence tomography (OCT) were small: four patients 
initially developed macular folds and two persisted until 4 weeks postoperatively, 
but visual acuities remained good. 
Based on these studies, we demonstrated that DS is effective in lowering IOP 
in NTG, EXG, and POAG. Even very low IOP between 9 to 10 is achievable. Use 
of MMC results in lower IOP and fewer postoperative interventions, such as GP 
and needlings. MMC use was without significant risk of serious complications or 
adverse effects. Rate of GP is close to 100 % when follow-up is long. EXG eyes 
may have altered fibrotic response to DS, which may favor MMC use. DS is a safe 
procedure, with only relatively small changes in anterior and posterior structures 
and a low rate of irreversible decrease in BCVA.
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INTRODUCTION
Glaucoma is one of the leading causes of irreversible blindness. Worldwide, 58 
million people had POAG in 2015 but this number is estimated to rise to 75 million 
by 2025 (Kapetanakis et al. 2016). The majority of growth in patient number comes 
from the developing world. In Finland there were 84.000 glaucoma patients in 
2013 with a higher prevalence among those over 70 years of age (Hirvelä et al. 
1994). The number of glaucoma patients has been increasing by 2.5% annually, 
and their number in Finland is expected to rise to 100,000 in 2020. Glaucoma is 
mostly asymptomatic in the early phase of the disease, and half the patients are 
unaware of their glaucoma, even in developed countries (Mitchell et al. 1996).
The only evidence based method of treatment commonly used for glaucoma 
is IOP reduction. A 25% decrease in IOP from the pre-treatment level slows the 
progression rate of glaucomatous visual field damage (Heijl et al. 2002). A decrease 
in IOP can be achieved with topical glaucoma medication, laser treatments, or 
surgery to slow visual field damage progression. 
The principle of glaucoma surgical procedures is to reduce IOP by raising 
aqueous outflow. This is achieved by reducing aqueous outflow resistance by 
partially or completely penetrating the eyewall.
Although effective in IOP reduction, several adverse effects are associated 
with glaucoma surgery: shallowing of the anterior chamber, intraocular bleeding, 
bacterial infections, hypotony, and hypotony-related complications. Deep 
sclerectomy (DS) evolved in order to avoid the postoperative hypotony which 
occurs with other forms of glaucoma surgery. 
The aim of deep sclerectomy is an increase in the aqueous outflow caused 
by reducing outflow resistance. This is performed during surgery by peeling the 
posterior trabeculum and the roof of Schlemms canal after formation of a deep 
scleral pocket. Since the inner part of the trabecular meshwork is left intact, 
resistance to the aqueous outflow is partly maintained (Rossier et al. 2000) and IOP 
decreases slower than with trabeculectomy. DS is classified as a non-penetrating 
technique, since during uneventful DS, the eye wall is not completely penetrated.
This study was undertaken to find the effect of DS when aiming for low 
postoperative IOP. MMC is commonly used in glaucoma surgery, especially with 
this aim. A detailed study of the additional effect of MMC use with DS on lowering 
IOP, as well as its adverse effects, was needed. I aimed to study the IOP-lowering 
effect of DS in EXG, which is a common glaucoma subtype in Finland. Transient 
loss of BCVA is common after successful DS, and my aim was to learn the factors 
explaining it.
12
REVIEW OF THE LITERATURE
1 GLAUCOMA
Glaucoma is a chronic and progressive ophthalmic disease. It affects the eye by 
triggering apoptosis of ganglionic cells that travel from the retina to the optic 
nerve (Quigley et al. 1995). Clinically, it has a specific pattern of optic nerve head 
damage and subsequent deterioration in the visual field. Patients can be unaware of 
having glaucoma, since glaucoma can be asymptomatic for many years. The most 
common forms of glaucoma in Finland, primary open-angle glaucoma (POAG), 
exfoliation glaucoma (EXG), and normal-tension glaucoma (NTG), do not usually 
cause pain or other symptoms, and can therefore remain undetected until late in 
the disease, when subjective vision is affected.
High intraocular pressure (IOP) is a risk factor for glaucoma (Sommer 1989), 
but 30 to 50% of glaucoma patients, the ones suffering from NTG, have IOP in 
the normal range (Bonomi et al. 1998, Rotchford & Johnson 2002).
 Other risk factors for glaucoma are age (Rudnicka et al. 2006), myopia (Mitchell 
et al. 1999), exfoliation (Ekstrom 2012), and family history (Tielsch et al. 1994). 
Glaucoma is diagnosed in a clinical examination by an ophthalmologist assisted 
with visual field evaluation by automated perimetry and examinations of the optic 
nerve head and retinal nerve fiber layer with optical coherence tomography (OCT), 
Heidelberg retina tomography (HRT), and/or ocular fundus photography.
1.1 Maintenance of intraocular pressure
IOP is regulated by a balance between aqueous production and outflow. Aqueous 
is produced by non-pigmented epithelial cells of the ciliary body behind the iris. 
Aqueous production has been measured in healthy eyes as between 2.4 to 2.8 µl / 
min (Toris et al. 1999). The aqueous flows through the pupil to the anterior chamber 
and leaves the eye via two passive pathways: conventional and unconventional 
pathways.
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The conventional (trabecular) pathway consists of aqueous flowing through 
the trabecular meshwork into the canal of Schlemms. From this canal, aqueous 
is removed to the episcleral veins and into the venous circulation (Bill & Hellsing 
1965). 
The unconventional (uveoscleral) pathway consists of direct aqueous 
outflow through the uveal meshwork and anterior part of the ciliary muscle, 
to the suprachoroidal space and then out of the eye through the sclera (Bill & 
Hellsing 1965). Functions of these pathways have been considered different, so 
that outflow through the unconventional pathway is independent of IOP, unlike 
with the conventional pathway (Brubaker 2001). However, in another study, 
aqueous outflows of both pathways were decreased among patients with ocular 
hypertension (Toris et al. 2002). The unconventional pathway contributed 42% 
of the total outflow in patients with ocular normotension and 25% of those with 
ocular hypertension.
The mean volume of the anterior chamber is 196 µl (Fontana & Brubaker 1980), 
but the anterior chamber in those 20 to 30 years of age is larger compared to those 
over 60 (247 µl ±39 vs. 160 µl ±39, p<0.00001) (Toris et al. 1999). Theoretically, 
the entire aqueous volume of the anterior chamber changes every 60 to 90 minutes. 
1.2 Open-angle glaucoma subtypes 
Glaucomas with normal anterior chamber angle structures and angle width are 
termed open-angle glaucomas. These can be further divided into primary and 
secondary open-angle glaucomas (Foster et al. 2002).
1.3 Primary open-angle glaucomas 
These glaucomas are chronic, progressive optic neuropathies with common 
characteristic changes in the optic nerve head and retinal nerve fiber layer. No 
other ocular disease or congenital anomaly is present. Retinal ganglion cell death 
leads to visual field loss, and these glaucomas can be asymptomatic until visual 
field loss is severe.
High IOP is the most important risk factor (Sommer et al. 1991). Other risk 
factors are age (Rudnicka et al. 2006), race (African ancestry) (Rudnicka et al. 
2006), myopia (Mitchell et al. 1999), positive family history (Tielsch et al. 1994), 
diabetes (Klein et al. 1994), optic disk hemorrhage (Hollands et al. 2013) and lower 
diastolic perfusion pressure (Tielsch et al. 1995).
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The most common form of primary open-angle glaucomas is the high-pressure 
variant of the disease. IOP is measured in ophthalmic examinations above the 
statistically determined “normal” level of 21 mmHg. Characteristic glaucomatous 
changes are detectable by means of further ophthalmologic studies. This high-
pressure variant is clinically referred to as primary open-angle glaucoma (POAG). 
In POAG, IOP is too high because aqueous outflow in trabecular meshwork is 
impaired. 
The normal pressure variant of primary open-angle glaucoma is often clinically 
termed normal tension glaucoma (NTG). It can be debated whether NTG is 
one spectrum of POAG or is a different disease entity. IOP is measured in the 
normal range, (21 mmHg or below) in ophthalmologic examinations with NTG. 
Hemorrhages of the optic nerve head may be present. 
Diastolic perfusion pressure plays a role in developing glaucomatic damage of 
the optic nerve head in both NTG and POAG. Perfusion pressure is blood pressure 
minus IOP, and low diastolic perfusion pressure is a risk factor for glaucoma 
(Tielsch et al. 1995). Blood flow to the optic nerve head (ONH) is autoregulated 
to remain stable despite changes in the IOP and blood pressure (BP). However, as 
the ONH blood flow autoregulation is defective in glaucoma (Hafez et al. 2003), 
an increase in IOP or decrease in BP will compromise ONH blood flow. Thus, 
problems in blood pressure autoregulation (nocturnal dippers) may explain some 
glaucoma damage occurring at lower IOP levels. IOP affecting the shape of the 
lamina cribrosa (Quigley & Addicks 1981) and development of retinal damage in 
the peripapillar area (Buus & Anderson 1989) have been under speculation as 
explanations for glaucomatous damage in optic nerve. The effect of translaminar 
pressure (difference of intraocular and intracranial pressures) in NTG has been 
speculated upon, but it seems controversial (Pircher et al. 2017).
If primary open-angle glaucoma is diagnosed between the ages of 10 and 35 it 
is considered primary juvenile glaucoma.
1.4 Secondary open-angle glaucomas 
Secondary open-angle glaucomas are caused by ophthalmic or systemic diseases, 
drugs, or treatments. By definition, the anterior chamber angle is open, with no 
angle pathology present. ONH changes and visual field deterioration may resemble 
those found in primary open-angle glaucomas.
Open-angle glaucoma with the presence of exfoliation material is called 
exfoliation glaucoma (EXG). The pathogenesis of exfoliation syndrome (EXS) is 
by formation of dandruff-like exfoliation material in the ocular structures, first 
discovered by Finnish ophthalmologist Lindberg in his thesis of 1917 (Tarkkanen 
& Kivelä 2002).
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When exfoliation material accumulates in the trabecular meshwork, ocular 
outflow can be reduced. This can lead to a slow but severe IOP rise. EXS is associated 
with weakening of lens zonules, which leads to an increase in risk of complications 
in cataract surgery, ultimately even luxation of the crystalline lens or IOL into 
the vitreous cavity. In slit-lamp examination, exfoliation material is detectable on 
the crystalline lens surface or pupillary border. The pupillary border can have a 
“moth-eaten” appearance in slit-lamp examination, and pupillary dilatation can 
be substantially weakened.
EXS prevalence is geographically restricted; it is common in Nordic countries 
(Hirvelä et al. 1995, Arnarsson et al. 2007) but also in Greece its prevalence is 
11.9% among those over 60 (Topouzis et al. 2007). In Australia and Asia, however, 
EXS is uncommon (Mitchell et al. 1999, Miyazaki et al. 2005).
Mutation of the lysyl oxidase-like (LOXL1) gene, found in 2007 (Thorleifsson 
et al. 2007), explains most of the EXS in Nordic countries. The LOXL1 mutation 
is common in many other areas without a high prevalence of EXS, and recently 
environmental factors, epigenetics, and other genes are considered to explain EXS 
development in part (Anastasopoulos et al. 2015).
Exfoliation syndrome promotes IOP, and this leads to an increased risk of 
glaucoma (Ekstrom 2012). Exfoliation syndrome may also reduce stiffness of the 
lamina cribrosa (Braunsmann et al. 2012) and affect glaucoma development.
In EXG, visual field damage and damage progression can be more severe than 
in POAG (Olivius & Thorburn 1978).
Pigmentary glaucoma is another form of secondary open-angle glaucomas. 
Pigment granules are released from the posterior surface of the iris, possibly due 
to the iris rubbing against crystalline lens zonules (Campbell 1979). As pigment 
granules are released into the aqueous fluid, they accumulate in the trabecular 
meshwork, and aqueous outflow thus decreases. Pigment glaucoma may induce an 
acute periodical rise in IOP, with sensations of pain and haloes around lights. Iris 
retroillumination or accumulation of melanin pigment on the corneal endothelium 
may occur in slit-lamp examination. Accumulation of melanin is visible with 
gonioscopic examination of anterior chamber angle. 
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2 MEDICAL TREATMENT OF GLAUCOMA
2.1 Drugs affecting aqueous production
Decreasing aqueous production is a useful way to reduce IOP. Beta-blockers 
(timolol, timolol maleate, betaxolol), alpha-agonists (brimonidine, apraclonidine) 
and carbonic anhydrase inhibitors (dorzolamide, brinzolamide, acetazolamide) 
are common glaucoma medications. They reduce aqueous production of ciliary 
epithelium. Their IOP-lowering effect is between 22 and 25% (Lippa et al. 1992, 
Schuman 1996, Scoville et al. 1988).
Apraclonidine and brimonidine also have some effect in increasing aqueous 
outflow and lowering episcleral venous pressure (Toris et al. 1995).
2.2 Aqueous outflow increasing drugs
Another alternative to reduce IOP is to raise aqueous outflow in the anterior 
chamber angle. 
Miotics (pilocarpine and derivatives) were the first topical glaucoma medications. 
They cause increased aqueous outflow by enhancing the outflow facility of the 
trabecular meshwork, doing so by affecting the longitudinal muscle of the ciliary 
body (Gaasterland et al. 1975). Miotics reduce IOP by 20 to 30%, but their clinical 
use has declined because of undesirable side-effects: miosis, burning sensations, 
brow ache, and headache.
Prostaglandin analogs (latanoprost, travoprost, tafloprost, unoprostone) form 
a group of drugs that reduce IOP by raising uveoscleral outflow (Toris et al. 
1997). Bimatoprost is a prostamide and has a slightly different metabolism from 
prostaglandins (Brubaker et al. 2001). Its IOP-lowering mechanism is to raise 
uveoscleral outflow, and its IOP-lowering effect is equal; however, it is clinically 
included among the prostaglandins. The IOP-lowering effect of prostaglandins 
as monotherapy has been better than that of beta-blockers (Alm & Stjernschantz 
1995, Boland et al. 2013).
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2.3 Combination therapy
Glaucoma medications can be combined in order to achieve a greater IOP-
lowering effect (Alm et al. 1995). Combination therapy can be instilled in individual 
components or fixed combinations. One common fixed combination product, 
latanoprost-timolol maleate (Xalcom), reduced IOP 1.9 mmHg more than did 
timolol maleate and 1.2 mmHg more than did latanoprost alone (Higginbotham et 
al. 2002). Latanoprost, travoprost and taflurost are available in fixed combinations 
with timolol (Brief et al. 2010, Pfeiffer et al. 2010, Pillunat et al. 2017). All 
prostaglandin fixed combination therapies show an additional IOP lowering effect 
compared to monotherapy alone, with good patient tolerability. Brinzolamide and 
dorzolamide are used with timolol in fixed combinations, and their IOP lowering 
effects have been similar (Manni et al. 2009). The only fixed combination without 
timolol combines brimonidine and dorzolamide.
2.4 Side-effects of topical glaucoma medication
Topical glaucoma medications can have many adverse effects, both local and 
systemic, and some of them are severe; contact allergy and eye redness are the 
most common. Miotics can produce accommodation spasm, visual disturbances, 
miosis, headache, and brow ache as local adverse effects (Zimmerman & Wheeler 
1982). Gastrointestinal symptoms have been reported as systemic side-effects.
Beta-blockers may have severe systemic side effects: cardiovascular ones 
and worsening of asthma symptoms (Waldock et al. 2000). Carbonic anhydrase 
inhibitors´ systemic side-effects include electrolyte imbalance, blood glucose level 
variations, and neurologic symptoms (Epstein & Grant 1977).
Prostaglandins commonly produce local adverse effects: contact allergy, eyelash 
growth and bristle, changes in iris- and eyelid pigmentation and hyperemia (Alm 
& Stjernschantz 1995, Inoue et al. 2012).
Some of the adverse effects introduced by glaucoma medication are due 
to benzalkonium chloride (BAC), which is used as a preservative in glaucoma 
medication products. BAC may cause corneal irritation, conjunctival redness, and 
allergic reactions (Uusitalo et al. 2010).
Since adverse effects can be severe, some patients become intolerant to glaucoma 
medication and need laser or surgical treatment for glaucoma later.
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3 LASER TREATMENT OF GLAUCOMA
3.1 Laser trabeculoplasty
Laser trabeculoplasty is glaucoma therapy aimed at the safe lowering of IOP. Argon 
laser trabeculoplasty was introduced in 1979 (Wise & Witter 1979). Argon laser 
applications are delivered to trabecular meshwork under topical anesthesia with 
help of a gonioscopic lens in order to increase aqueous outflow.
Later, selective laser trabeculoplasty (SLT) was developed (Latina & Park 1995). 
SLT is a laser procedure that aims to reduce IOP by causing an increasing aqueous 
outflow. This is achieved by applying Q-switched 532 nm energy pulses to the 
trabecular meshwork in the anterior chamber. After instillation of anesthetizing 
drops, gonioscopic lens is introduced into the eye. Then approximately 50 to 
100 laser pulses are applied to 180 or 360 degrees of trabecular meshwork. SLT 
treatment does not create mechanical damage to the structures of the trabecular 
meshwork (Kramer & Noecker 2001), and the IOP-lowering effect is explained by 
biomechanical and cellular alterations (Wong et al. 2015). 
The IOP-lowering effect of SLT is between 3.6 and 6.8 mmHg after 1 to 3 years 
of follow-up (Bovell et al. 2011, Katz et al. 2012, Koucheki & Hashemi 2012). The 
most common adverse effects of SLT are anterior chamber inflammation in 0 to 
89%, transient IOP rise in 0 to 62%, and eye pain in 0 to 58% of patients (Bovell 
et al. 2011, Koucheki & Hashemi 2012, Wong et al. 2015). However, IOP reduction 
after SLT is transient, with a failure rate of 44 to 50% after 1 to 3 years of follow-
up, when failure is determined as IOP reduction of less than 20% or continuation 
of glaucoma medication (Bovell et al. 2011, Koucheki & Hashemi 2012). Since SLT 
is well tolerated, it can be used as first-line treatment of open-angle glaucomas or 
in addition to topical glaucoma medication. 
3.2 Laser cyclophotocoagulation
Cyclophotocoagulation can be performed by laser. Among different wavelengths 
in use, are 810 nm infrared, 647 nm krypton, and 670 nm diode laser. Lasers 
can function in a continuous mode (Mistlberger et al. 2001, Schlote et al. 2001) 
or in a recently developed micropulse mode (Tan et al. 2010). The IOP-lowering 
effect of laser cyclophocoagulation procedures is achieved by lessening aqueous 
production of ciliary body by damaging aqueous-producing epithelial cells. 
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Treatment is performed, after retrobulbar anesthesia, by holding laser probe against 
the conjunctiva a few millimeters posterior to the limbus. Then laser energy is 
provided through the sclera to affect the underlying ciliary body. Treatment is rather 
straightforward and can be repeated if necessary. Laser cyclophotocoagulation is 
usually reserved for late-stage glaucoma when other methods of treatment have 
failed or are considered inefficient. However, cyclophotocoagulation can be used 
as the primary treatment in neovascular glaucoma (Yildirim et al. 2009).  
Success, an IOP of <21 or 22 mmHg, can be achieved in 68 to 80% of eyes after 
a one-year follow-up with medication allowed (Mistlberger et al. 2001, Schlote 
et al. 2001, Tan et al. 2010). After 2 years of follow-up, the success rate declines, 
however, to 50% (Mistlberger et al. 2001), with 25% of treated eyes in need of 
two or more cyclophotocoagulations during first 3 to 4 years (Raivio et al. 2008). 
Adverse effects are anterior chamber inflammation at 64-100%, loss of >2 lines of 
visual acuity at 13-19%, hyphema at 7-18% and phthisis bulbi in 0-8% (Mistlberger 
et al. 2001, Schlote et al. 2001, Delgado et al. 2003, Tan et al. 2010).
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4  INDICATIONS OF GLAUCOMA SURGICAL  
 TREATMENT
The most important indications for glaucoma surgery are as follows: overly high IOP 
despite maximal topical glaucoma medication, progression of visual field defect and 
intolerance to topical glaucoma medication. The IOP-lowering effect of glaucoma 
medication can weaken when used for many years, and although good IOP control 
has been achieved after initiation of topical medication, glaucoma surgery may 
be necessary after a few years (Brooks & Gillies 1988). If the visual-field defect 
progresses despite the maximum tolerated IOP medication, glaucoma surgery may 
be indicated (Jay & Murray 1988). In glaucoma patients, IOP may show diurnal 
variation, and the optic nerve may suffer damage when IOP is elevated even for 
a short time (IOP spike). For some patients, glaucoma surgery reduces these IOP 
spikes and the diurnal IOP fluctuation more than does topical glaucoma medication 
(Medeiros et al. 2002). Glaucoma medication may cause adverse effects on treated 
eyes such as redness, irritation, and inflammation. These effects can be induced 
by the glaucoma medication itself (Alm & Stjernschantz 1995) or by benzalkonium 
chloride used as a preservative (Uusitalo et al. 2010).
Some elderly people may have difficulties using topical medication on their 
eyes. Patients with diseases affecting their cognitive behavior (Alzheimers 
disease, alcohol abusers, mental illnesses) may be unable to comply with regular 
medication use.
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5 PENETRATING FILTRATION SURGERY
5.1 Trabeculectomy 
Trabeculectomy, introduced in 1968 (Cairns 1968), has become the gold standard 
among glaucoma surgical procedures. The conjunctiva is opened with a limbus- or 
fornix-based incision. As with DS, it is very important to achieve good hemostasis in 
order to avoid postoperative scarring. The scleral flap is performed with a surgical 
knife. The thickness of the flap is about half- to one-third of scleral thickness, and 
the flap can be rectangular or triangular. Paracentesis to the anterior chamber is 
performed so that the volume and shape of the anterior chamber can be maintained 
when needed. The flap is lifted and turned over the peripheral part of the cornea. 
After formation of the scleral flap, the antimetabolites MMC or 5-fluorouracil (5-
FU) can be applied. Polyvinyl alcohol sponges soaked with MMC are then inserted 
under the scleral flap and conjunctiva for 1 to 3 minutes, then removed, and the 
antimetabolite is carefully washed away with a balanced salt solution (BSS). MMC 
concentration in use varies between 0.02 to 0.4 mg/ml (Kitazawa et al. 1993, 
Robin et al. 1997). The surgical opening is continued to the peripheral part of the 
cornea, and finally a perforation is performed to the anterior chamber. A full-
thickness block is removed by a punch instrument from the peripheral part of 
the cornea and anterior part of the sclera. Perforation to the anterior chamber 
or corneoscleral block removal usually results in rapid flow of aqueous from the 
wound. Then surgical iridectomy is performed by forceps and scissors. Closure of 
the scleral flap is secured with two or more non-absorbable sutures. By adjusting the 
tightness of these sutures, the surgeon can affect the amount of aqueous filtration 
and IOP in the immediate postoperative time-period. The conjunctiva is closed with 
continuous or interrupted absorbable sutures. The use of subconjunctival devices 
with trabeculectomy is comparable to the application of MMC with regard to long-
term success rate (Ji et al. 2015). The later-introduced safe-surgery trabeculectomy 
is another alternative. The anterior chamber maintainer and adjustable sutures, 
which can be loosened postoperatively, lead to fewer postoperative complications 
and allow adjustment of aqueous outflow (Stalmans et al. 2006). 
The IOP-lowering effect of trabeculectomy is well documented (Bindlish et al. 
2002, Stalmans et al. 2006, Gale & Wells 2008, Landers et al. 2012). In the longer 
term, mean IOP is between 10 and 12 mmHg after 3 to 5 years (Bindlish et al. 
2002, Gale & Wells 2008). Complications of traditional trabeculectomy include 
hyphema in 25%, hypotony 24 to 43%, hypotony maculopathy 9%, and choroidal 
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detachment 14% (Bindlish et al. 2002, Edmunds et al. 2002, Landers et al. 2012). 
With the later-introduced safe surgery trabeculectomy, some complication rates 
are lower: hyphema 5% and choroidal detachment 3 to 9% (Stalmans et al. 2006, 
Gale & Wells 2008).  
Cataract progression occurs postoperatively: in 5 years after trabeculectomy, 
55% of eyes need cataract operation (Bindlish et al. 2002), and within 3 years 
after safe-surgery trabeculectomy (Gale & Wells 2008), only 18% need a cataract 
operation. With modern postoperative antibiotics, endophthalmitis is rare after 
trabeculectomy, with an incidence of 0.3 to 1.5% (Bindlish et al. 2002, Edmunds 
et al. 2002, Stalmans et al. 2006).
5.2 Glaucoma tube surgery
Glaucoma tube surgery is another alternative to filtration procedures. In tube 
surgery, aqueous fluid flows out of the anterior chamber through a tube connected 
to an outflow chamber; this facilitates outflow. When the tube is inserted, the 
conjunctiva is opened in similar fashion as with filtration surgery. The outflow 
chamber is sutured to the surface of the sclera with two knots. An opening to 
the anterior chamber is performed by needle. (A flap of sclera can be created to 
help protect the tube from penetration of the overlying conjunctiva during the 
postoperative period.) The tube is inserted under the scleral flap and through 
the opening to the anterior chamber. Care needs to be taken that the tube, when 
inserted, does not touch any intraocular structures: the corneal endothelium, the 
iris or the lens. Tube-length must be adjusted accordingly. The most common 
types of tube in use are the Molteno, Molteno3, Ahmed, and Baerveldt implants 
(Molteno 1969, Smith et al. 1993, Coleman et al. 1995, Välimäki 2012). The 
Molteno and Baerveldt allow direct outflow of aqueous via the tube to the outflow 
chamber. This may result in postoperative hypotony, so some modifications can 
avoid this complication with these implants. The outflow tube can be ligated with 
an absorbable suture, or the tube can be internally occluded with a removable 
suture (Hong et al. 2005).
The Ahmed is designed differently: to avoid postoperative hypotony, this outflow 
tube has a one-directional flow restrictor designed to open at a pressure of 8 mmHg 
(Coleman et al. 1995). 
Other modifications to the original implants to achieve lower postoperative 
IOP include introduction of a larger outflow chamber with the Baerveldt, and a 
double outflow chamber with the Molteno (Heuer et al. 1992, Smith et al. 1993). 
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After insertion of tube implants, a hypertensive period may occur 1-13 weeks 
postoperatively and it is more common after Ahmed than Baerveldt implantation 
(Nouri-Mahdavi & Caprioli 2003). During this period, the IOP can rise to between 
35-55 mmHg before falling to a lower level after the 12th – 16th postoperative 
weeks (Molteno et al. 1976).
Previously, tube surgery was reserved for more complex cases of glaucoma 
and for reoperation when filtration surgery had failed. Nowadays, a shift towards 
primary tube surgery has been validated by previous results (Molteno et al. 2011, 
Gedde et al. 2012b, Välimäki & Ylilehto 2014, Islamaj et al. 2018). Postoperative IOP 
after insertion of Baerveldt shunt was 14.4 mmHg ±6.9 after 5 years’ follow-up in 
the multicenter Tube Versus Trabeculectomy study (Gedde et al. 2012b). The same 
study showed that the Baerveldt implant had a better success rate compared to 
trabeculectomy with MMC in patients with prior cataract surgery or trabeculectomy. 
The number of early postoperative complications and reoperation for glaucoma 
was higher following trabeculectomy with MMC than Baerveldt procedure (Gedde 
et al. 2012a, Gedde et al. 2012b). Insertion of a sequential glaucoma drainage 
implant in a piggyback manner is possible if extra drainage with lower IOP is 
needed during the follow-up (Välimäki 2015). The tube can also be introduced into 
the posterior chamber, and the IOP control appears comparable to conventional 
anterior chamber placement (Kolomeyer et al. 2015, Rososinski et al. 2015). In 
addition, postoperative 50% corneal graft failure rate has been reported after this 




The conjunctiva is opened either from the limbus or from the conjunctival fornix. 
Care must be taken to avoid excessive bleeding, which could promote postoperative 
scar-formation. 
The superficial scleral flap is first incised with a surgical knife. A superficial 
flap is usually rectangular and 5 x 5 mm (Kozobolis et al. 2002, Ollikainen et al. 
2011), but even a 4 x 5 mm superficial flap has been used (Audren et al. 2006). 
A superficial flap, in thickness, is approximately one-third the scleral thickness. 
The superficial flap is then opened and turned aside. 
Mitomycin-C (MMC) can be used to lessen postoperative scarring. Polyvinyl 
alcohol sponges soaked with MMC (0.02 to 0.4 mg/ml) (Anand 2011, Mansouri 
et al. 2011) are placed under the conjunctiva and superficial scleral flap for one 
to three minutes. Then the sponges are removed, and the subconjunctival and 
intrascleral spaces are rinsed thoroughly with balanced salt solution (BSS). 
Then the deeper flap is excised in similar fashion. The deeper flap can be smaller 
than the superficial flap (Anand et al. 2011, Ollikainen et al. 2011), and the shape of 
the deeper flap is rectangular (Shaarawy et al. 2001, Anand et al. 2011) or triangular 
(Kozobolis et al. 2002). The depth of the deeper flap is about 95% of scleral depth, 
so that the chorioidea can be faintly observed through the remaining sclera. 
The deeper flap is excised anteriorly until the canal of Schlemm. Excision 
is continued further anteriorly to the peripheral cornea in order to perform a 
trabeculo-Descemet’s window. Then the base of the deeper flap is cut in the clear 
cornea to achieve an intrascleral empty space where fluid from the anterior chamber 
can percolate after the operation. 
Structures of Schlemm’s canal are identified after excision of the deeper flap. 
Then the outer part of the trabecular meshwork is seized with fine forceps. The 
outer part of the trabecular meshwork is carefully peeled, but if too much tissue 
is peeled, this leads to a small or large tear of Descemet´s window. A smaller tear 
is easier to handle, since the anterior chamber is usually maintained. A large tear 
leads to shallowing of the anterior chamber, and the operation usually has to be 
converted to a trabeculectomy with widening of the scleral opening to the anterior 
chamber and subsequent surgical iridotomy. If excision of the outer part of the 
trabecular meshwork is too superficial, this may lead to inadequate outflow of 
anterior chamber fluid and a too-high postoperative IOP. When the trabecular 
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meshwork is peeled correctly, and no perforation to the anterior chamber occurs, 
fluid from the anterior chamber begins to slowly percolate through the inner part 
of the trabecular meshwork, which can be seen with a surgical microscope. The 
anterior chamber is maintained, and risk of bleeding into the anterior chamber 
is minimal, because fluid percolation is controlled by the remaining trabecular 
meshwork.
Space created inside the sclera can be postoperatively maintained by inserting 
an implant into the remaining scleral bed and securing it with a knot. 
Then, whether or not an implant is inserted, the superficial flap is closed. It 
is sutured with non-absorbable material from the corner(s) and the knots are 
buried. The conjunctiva is finally closed with absorbable sutures. Suturing of the 
conjunctiva can be done with interrupted or continuous sutures. This final suturing 
must be careful in order to avoid tearing of the conjunctiva or a too loosely closed 
conjunctiva, both of which could lead to postoperative leakage of aqueous out of 
the eye. 
Aqueous should not flow uninterrupted out of the eye, since this could lead to 
sight threatening complications, such as endophthalmitis (Soltau et al. 2000). If 
such postoperative leaking of aqueous is encountered, there are several options for 
treatment. It can be treated with follow-up only, with placement of a therapeutic 
contact lens, or by suturing the conjunctiva in the operating room with the aid of 
an operating microscope. A filtering bleb can be seen under the conjunctiva on 
the first postoperative day.  
6.2 Implant types
In DS, part of the sclera and cornea is removed surgically under the superficial 
flap, and a sclerocorneal space, or pocket, is created. In order to maintain this 
sclerocorneal pocket open and to avoid postoperative scarring, implants have been 
developed: the principle of the implants is absorbable material partially filling 
the sclerocorneal pocket during the first postoperative months, after which the 
implant is absorbed. In studies concerning the IOP-lowering effect of implants, 
results are controversial. In two studies, use of collagen implants resulted in a 
better postoperative success rate and IOP control (Sanchez et al. 1996, Shaarawy 
et al. 2004). All studies, however, do not find the same result (Mesci et al. 2012).
Several implants are in use at present. The Aquaflow collagen implant (STAAR 
Surgical AG, Nidau, Switzerland) is a 1-mm wide and 4-mm long cylinder of collagen 
(Demailly et al. 1996, Karlen et al. 1999). It is placed radially on the exposed scleral 
bed of the deep sclerectomy dissection and secured with a 10/0 non-absorbable 
suture. Resorption of the implant takes 6 to 9 months, during which the intrascleral 
space is held open to enhance filtration (Chiou et al. 1998b).
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Another material for implants is the hyaluronic acid used in the SK-GEL implant 
(Corneal Laboratories, Paris, France). The SK-GEL implant is positioned in the 
deep sclerectomy dissection but with no suture needed (Sourdille et al. 1999). It is 
biocompatible, begins to dissolve after 6 months postoperatively and is replaced by 
scar or resorbed in 2 of 30 patients during the first 12 months (Marchini et al. 2001).
The third option is the hydrophilic acrylic implant T-flux (IOLTech Laboratories, 
La Rochelle, France). It is a non-absorbable T-shaped implant 8 mm in width 
and 2.75 mm in height (Ravinet et al. 2004). The arms of the T-flux are inserted 
into the openings of the Schlemms canal, and it is secured with a non-absorbable 
suture to the scleral bed (Mendrinos et al. 2008).
6.3 Trabeculo-Descemet’s membrane
When the outer layer of the trabecular meshwork is peeled during DS, a thin 
layer of tissue remains as a barrier between the anterior chamber and the deep 
sclerectomy pocket. This barrier is called the trabeculo-Descemet’s membrane 
(TDM) or trabeculo-Descemet’s window. It is a transparent layer of inner trabecular 
meshwork. An intact TDM is considered to be a major factor explaining the different 
complication profiles observed when comparing DS and trabeculectomy, especially 
concerning flat anterior chamber and postoperative choroidal detachment 
(Mermoud et al. 1999). 
6.4 Aqueous resorption mechanisms
Several resorption routes exist after aqueous has flowed through the TDM. When 
aqueous flows through the TDM and under the scleral superficial flap, most of 
it flows beside the sutured superficial flap into the subconjunctival space, and 
a subconjunctival bleb is formed. After DS, a subconjunctival filtering bleb 
can already be found in most of the cases on the first postoperative day. These 
subconjunctival blebs vary in height and appearance; a clinically shallow and 
diffuse appearance is more desirable than a high profile with thick walls. For 
study purposes, subconjunctival blebs can be divided into four categories using 
ultrasound biomicroscopy: low reflective, high reflective, encapsulated, and 
flattened, described after trabeculectomy with MMC (Yamamoto et al. 1995). This 
filtering subconjunctival bleb can persist even years after successful DS (Chiou et 
al. 1998b, Marchini et al. 2001). 
During deep sclerectomy, a deep scleral flap is removed surgically, and an 
intrascleral space, or intrascleral bleb, is formed. When aqueous percolates 
through the TDM, it flows through this intrascleral bleb. One suggestion is that 
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new intrascleral drainage vessels grow after DS, possibly affecting aqueous outflow 
(Delarive et al. 2003). Several types of implant can hold this intrascleral space 
open. One year postoperatively, an intrascleral bleb could be found with ultrasound 
biomicroscopy in 90% of the eyes treated with an intrascleral implant (Kazakova 
et al. 2002). Postoperative formation of an intrascleral bleb seems to be clinically 
important for DS success. The height of the intrascleral bleb as measured by OCT 
has been correlated with lower postoperative IOP (Mavrakanas et al. 2010).
During DS, 10% or less of scleral thickness is left intact in the area of the deeper 
scleral flap. Aqueous humor can flow into the suprachoroidal space postoperatively 
via an outflow route that can be examined by ultrasound biomicroscopy (UBM). A 
suprachoroidal bleb imaged as suprachoroidal hyporeflectivity in UBM examination 
is apparent in 50 to 80% of eyes after DS (Chiou et al. 1998b, Perez-Rico et al. 
2014). The clinical role of suprachoroidal outflow, however, is still not clear.
The Schlemms canal is opened and part of its wall is removed with DS. This 
might allow aqueous to drain from intrascleral space into the Schlemms canal and 
further into the episcleral veins (Mendrinos et al. 2008). This route of aqueous 
outflow may be important after viscocanalostomy (Stegmann et al. 1999), but its 
relevance after DS is unknown.
6.5 Goniopuncture
During the postoperative period, filtration of anterior chamber fluid under the 
conjunctiva can decrease. Very commonly this occurs because outflow resistance in 
Descemet’s window has increased. Treatment is perforation of Descemet’s window 
with YAG-laser goniopuncture (GP). 
GP is performed as follows: the eye is anesthesized with oxybuprocain eye 
drops (or similar). One or a few drops of pilocarpine are instilled into the eye to 
stabilize the iris. The gonioscopic lens is introduced into the eye, and the Descemet’s 
window is visualized. Then one pulse or several pulses are fired at the Descemet’s 
window with a neodymium-doped yttrium aluminum garnet (YAG) laser. When 
a hole is achieved in the Descemet’s membrane, fluid outflow from the anterior 
chamber can be visualized with a gonioscopy lens; IOP decreases within minutes. 
GP turns deep sclerectomy from a non-perforating technique to perforating, 
because a hole between the anterior chamber and subconjunctival bleb is opened. 
GP is normally performed in the postoperative period weeks or even years after 
the initial operation, when the conjunctiva has healed.
Mean time of GP after DS is 10 to 12 months, mean IOP before GP ranges 
from 20 to 23 mmHg and decreases about 10 mmHg in the immediate post-GP 
period (Anand & Pilling 2010, Di Matteo et al. 2016). In these studies, mean IOP 
was between 11 and 14 mmHg 2 years after GP. The rate of GP after DS has a 
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large variation from 24 to 87% with a tendency toward a higher percentage with 
longer follow-up (Rekonen et al. 2006, Bissig et al. 2008, Ollikainen et al. 2011, 
Bettin et al. 2016). 
After GP, several possible complications can occur, of which iris incarceration 
into the hole of the Descemet’s window (13%), hypotony (4%) and microscopic 
hyphema (4%) are the most common (Anand & Pilling 2010, Di Matteo et al. 
2016). The rate of iris incarceration into the Descemet’s window after GP can 
possibly be reduced with preoperative laser iridotomy and Argon laser iridoplasty 
(Di Matteo et al. 2016).
If parts of the iris are incarcerated into the hole of the Descemet’s window, and 
IOP rise occurs, there are several treatment options. First, argon laser applications 
can be applied to the peripheral iris with a gonioscopy lens (Argon laser iridoplasty) 
(Anand & Pilling 2010). Second, the iris can be treated with YAG laser applications 
in a manner similar to this on the base of iris as well as by creating a new opening 
in the Descemet’s window (Vasquez Perez et al. 2013). The third option is surgical 
removal of iris tissue from the Descemet’s window in the operating room if IOP 
remains too high despite laser treatments. 
6.6 Needle revision
Postoperative subconjunctival scarring can lead to formation of a cystic filtration 
bleb, which is usually balloon-like, with clearly distinguishable walls. Cystic bleb 
formation can be treated with needle revision.
The eye is anesthesized with drops similarly as with GP. The patient is seated 
with their head positioned on the biomicroscope, or alternatively in the operating 
room. The upper eyelid is lifted with a cotton swab. The subconjunctival space is 
then entered with a straight or bent needle, one 27 g in our hospital, usually from 
the temporal side. The cystic bleb is punctured with the needle, and its wall can be 
opened further by cutting it with the side of the needle. This leads to increasing fluid 
filtration under the conjunctiva, which can be observed with the biomicroscope. 
If sufficient fluid filtration or a subsequent IOP drop is not achieved, the needle 
can be inserted under the scleral flap.  
After needling, antimetabolites, 5-fluorouracil (5-FU), or mitomycin-c (MMC) 
(Koukkoulli et al. 2015), can be injected under the conjunctiva. These antimetabolites 
are used to lessen scar formation of the conjunctiva. Postoperatively, patients 
receive antibiotic and cortisone drops for a few days to several weeks. 
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Only one study concerns long-term effects of needle revision after DS (Koukkoulli 
et al. 2015). In that study of needle revision with MMC adjunction, a complete 
success rate of IOP < 18 mmHg or 20% reduction without glaucoma medication 
allowed was achieved in 57% of cases after 3 years of follow-up. The mean number of 
needle revisions needed was 1.6, ranging from 1 to 4. Needle revision had significant 
complications: delayed hypotony in 7.6% and endophthalmitis in 1.5% (one eye). 
MMC concentration was 0.01 or 0.02 mg/ml in most cases. 
6.7 Surgical revision
Sometimes postoperative scar formation is too thick to be treated with needling 
alone. If fluid filtration under the conjunctiva is dramatically decreased, and needle 
revision has been insufficient, the patient may need surgical revision of the filtration 
bleb. Surgical revision is carried out in the operating room. The eye is anesthesized 
with drops or with a parabulbar block. The conjunctiva is opened surgically, and 
the underlying scar tissue or thickened tenons capsule or both are excised. The 
superficial scleral flap can be opened. The conjunctiva is closed with sutures as in 
the initial DS. When surgical revision is performed, the antimetabolites MMC or 
5-FU can be injected under the conjunctiva. 
To the best of my knowledge, no published studies consisting only of DS patients 
seem to exist. One study of surgical revision does include DS patients, although 
the majority, 45 of 54 eyes, had initially been performed by trabeculectomy or 
trabeculectomy combined with cataract procedure (Anand & Arora 2007). A 
thickened tenons capsule was excised in 41% of those eyes, MMC was used in 
all eyes, the scleral flap was opened and iridectomy performed when necessary. 
In that study all DS surgeries were performed with trabeculectomy as a revision 
operation. After 4 years, 39% of eyes achieved complete success; 43% of eyes 
required glaucoma medication.
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7 INDICATIONS FOR DEEP SCLERECTOMY
Traditionally, treatment of glaucoma begins with topical medication and laser 
treatments, such as SLT. Surgery may be necessary if IOP remains too high despite 
maximal tolerated glaucoma medication, if the visual-field defect progresses and 
medication cannot be added, if glaucoma medication cannot be tolerated because 
of adverse effects, or if compliance prevents its topical use (problems instilling 
eye-drops, Alzheimers, decrease in cognitive status). 
7.1 Open-angle glaucoma (POAG) 
In open-angle glaucoma resistance to aqueous outflow is considered too high, and 
the anterior chamber angle in POAG is considered anatomically normal, open and 
without angle anomalies affecting aqueous outflow. 
DS has a good IOP-lowering effect in POAG patients (Kozobolis et al. 2002, 
Bissig et al. 2008, Anand et al. 2011, Ollikainen et al. 2011, Bettin et al. 2016). In 
studies with the majority of their patients diagnosed as POAG, postoperative IOP 
after one year ranges from 13 to 17.3 mmHg with or without glaucoma medication 
(Kozobolis et al. 2002, Bissig et al. 2008, Anand et al. 2011, Ollikainen et al. 2011, 
Bettin et al. 2016). In the longer term, after 3 years, postoperative IOP ranges from 
11.1 to 18.7 mmHg with or without glaucoma medication. In one study, IOP 10 
years postoperatively was 12.2 mmHg (±4.7) with or without glaucoma medication 
(Bissig et al. 2008).
7.2 Normal tension glaucoma (NTG)
Among NTG patients, visual-field damage progresses with lower IOP than in POAG, 
and the target IOP is lower, usually between 10 and 14 mmHg. Trabeculectomy 
has been the gold standard among glaucoma-filtering procedures for NTG patients 
(Shum & Leung 2013), because the IOP-lowering effect of trabeculectomy among 
these patients is well documented (Membrey et al. 2000, Shigeeda et al. 2002, 
Jongsareejit et al. 2005, Jayaram et al. 2016). 
Some studies prior to 2010 included NTG patients (Bissig et al. 2008, Anand et 
al. 2011), but they were not analyzed as a subgroup. To the best of my knowledge 
there is no study of the IOP-lowering effect of deep sclerectomy in NTG patients 
alone. 
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The IOP-lowering effect of trabeculectomy has been reported in NTG patients 
(Membrey et al. 2000, Shigeeda et al. 2002, Jongsareejit et al. 2005, Jayaram 
et al. 2016) to be sufficient, with mean IOP of 10.6 -11.1 mmHg 3 years after the 
operation with success rates of 39 to 65 % with or without medication (Membrey 
et al. 2000, Jayaram et al. 2016).
7.3 Exfoliation glaucoma (EXG)
In EXG, accumulation of exfoliation material occurs in the juxtacanalicular tissue 
under the inner wall of Schlemm’s canal (Schlotzer-Schrehardt & Naumann 1995). 
This is the site of greatest resistance to aqueous outflow, and also the anatomical 
location at which DS is targeted. In several studies of DS with EXG patients, similar 
success rates were achieved with DS in EXG and POAG patients (Drolsum 2006). 
A more recent prospective study found similar results (Ollikainen et al. 2011), 
although goniopuncture was more common in the EXG group. Although these were 
relatively small studies with only 37 EXG patients as a maximum, they indicate 
that DS has a good effect on EXG. 
The number of studies on DS with EXG patients is limited. However, they show 
good IOP lowering effect (Drolsum 2006, Mendrinos et al. 2009, Ollikainen et 
al. 2011). One year postoperatively, IOP has been between 11 and 12 mmHg and 
in the longer term, after at least 3 years of follow-up, IOP has ranged from 11 to 
15.5 mmHg (Drolsum 2006, Mendrinos et al. 2009, Ollikainen et al. 2011), with 
a pressure drop of 13-17 mmHg with or without medication. The number of eyes 
in these studies has been 22 to 37.
7.4 Deep sclerectomy in other forms of glaucoma 
There are relatively few reports of DS in uveitic glaucoma patients, although it seems 
that good IOP control in the medium term can be achieved by DS with MMC. In 
a retrospective study of 43 eyes, preoperative IOP decreased from 33.6 mmHg to 
16.4 after 5 years follow-up, with 51% of eyes achieving IOP <19 mmHg without 
medication (Mercieca et al. 2017). In another prospective study of 33 eyes, IOP 
decreased from 37.2 mmHg to 14.7 mmHg after mean follow-up of 33 months (Al 
Obeidan et al. 2015), and 72% of eyes had final IOP < 21 mmHg without medication.
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There is a small number of published studies on pediatric glaucoma. One study 
of modified deep sclerectomy has been reported to show relatively good IOP control. 
With a preoperative IOP of 31.9 mmHg, 70% of eyes achieved an IOP between 6 
and 19 mmHg after 3 years of follow-up (Feusier et al. 2009). However, their deep 
sclerectomy technique was modified so that perforation to the anterior chamber 
and a surgical iridotomy were performed at the time of surgery.
Deep sclerectomy has been used in glaucoma associated with Sturge-Weber 
syndrome, but the result was not favorable (Audren et al. 2006). Postoperatively, 
6 out of 9 operated eyes (66%) required another glaucoma surgical procedure after 
2 years follow-up, with Kaplan-Meier survival of 0%. 
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8 CONTRAINDICATIONS TO DEEP SCLERECTOMY
Neovascular glaucoma is associated with the growth of small blood vessels in the 
anterior parts of the eye; these can grow into the anterior chamber angle. Because 
IOP reduction with DS is related to a functional conjunctival bleb and window of 
the Descemet’s membrane, neovascular glaucoma is a contraindication for DS. 
Angle-closure glaucoma is associated with narrowing or total closure of the 
anterior chamber angle. To achieve good IOP control with DS, a proper window 
of the Descemet’s membrane must be created. This can be impossible when 
the anterior chamber is narrow or closed, so angle-closure glaucoma and angle 
anomalies are contraindications for DS.
Contact lens wear is not a direct contraindication, but wearing contact lenses 
can be difficult postoperatively. Filtering bleb after trabeculectomy may introduce 
difficulties in contact lens fitting and wear (Pederson 2005). To my knowledge no 
studies of worsening dry eye symptoms after DS exist. However, dry eye symptoms 
in some patients may worsen after trabeculectomy in conjunction with MMC (Lam 
et al. 2015). Postoperative follow-up with performance of GP when necessary are 
mandatory after DS (Rekonen et al. 2006, Bissig et al. 2008, Ollikainen et al. 2011, 
Bettin et al. 2016). Patients’ ability to control visits should be taken into account 
when DS is scheduled.
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9 VISCOCANALOSTOMY
The first results of viscocanalostomy appeared in 1999 (Stegmann et al. 1999). The 
conjunctiva is opened in the usual manner and a superficial and deep scleral flap 
are made. Then the canal of Schlemm is unroofed. Viscoelastic material is injected 
into both of the opened lumens of the canal of Schlemm. Viscoelastic material is 
considered to open the canal of Schlemm and facilitate aqueous outflow from the 
anterior chamber. The superficial scleral flap is sutured tightly. Viscocanalostomy 
is based on the assumption that by increasing aqueous outflow with viscoelastic 
dilatation of Schlemm’s canal, no filtering bleb is necessary. Postoperative injections 
of 5-FU can reduce bleb fibrosis (Shaarawy et al. 2003). 
In studies of viscocanalostomy, postoperative IOP has been from 15.4 to 16.2 
mmHg after 5 years of follow-up, and two-thirds achieved IOP <18 mmHg without 
medication (Wishart et al. 2008, Grieshaber et al. 2015). The main adverse effects 
were microhyphema, microperforation, and cataract formation. A shallow anterior 
chamber and hypotony are very rare (Wishart et al. 2008, Grieshaber et al. 2015).
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10 CANALOPLASTY
Canaloplasty, a modification of viscocanalostomy, was introduced in 2007 (Lewis 
et al. 2007). The first phases of canaloplasty and viscocanalostomy are the same, up 
to the formation of the deeper scleral flap. Then, the opening of Schlemm’s canal 
is entered by a flexible catheter with a small light source in its tip. This catheter 
is carefully introduced into Schlemm’s canal until it travels the total 360 degrees; 
then it is retracted from the other opening of Schlemm’s canal, and a suture is 
tied to the tip. The catheter is then withdrawn from the Schlemm’s canal and 
the catheter pulls the suture into Schlemm’s canal. Viscoelastic material can be 
injected into the canal while the catheter is withdrawn. The ends of the suture are 
tied to secure it in place and apply tension to the inner wall of Schlemm’s and to 
open its lumen. Then the scleral flap and conjunctiva are closed in the same way 
as with viscocanalostomy.
In studies of POAG eyes, a mean postoperative IOP of 13.3 to 14.5 mmHg was 
reached after 18 to 36 months follow-up with or without glaucoma medication 
(Grieshaber et al. 2010, Koerber 2012). Postoperatively, transient microhyphema 
was reported in 70% of eyes. Detachment of the Descemet’s membrane and false 
passage of the catheter were less frequent (Grieshaber et al. 2010). 
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11 MINIMALLY INVASIVE GLAUCOMA  
 SURGERY (MIGS)
Since both topical medication and glaucoma surgical procedures opening the 
conjunctiva have their disadvantages, several methods and devices have been 
developed to achieve IOP lowering with fewer adverse effects. These are collectively 
termed minimally invasive glaucoma surgery (MIGS). MIGS procedures can be 
further divided into three categories based on the structure, or the site of the 
aqueous-outflow resistance they are designed to bypass. Current methods and 
devices allow us to bypass the aqueous into subconjunctival space, through the 
trabecular meshwork to Schlemm’s canal or to the suprachoroidal space. All MIGS 
procedures are performed ab interno through a peripheral corneal incision with 
minimal direct conjunctival surgical damage.
The XEN Gel implant (Allergan, Dublin, Ireland) offers a novel method for 
glaucoma surgery. It is a small tube made of porcine collagen and is inserted 
with an injector through a corneal peripheral incision, through Schlemm’s canal, 
perforating the sclera to the subconjunctival space. The function of the XEN gel 
implant is to increase aqueous outflow under the conjunctiva. Subconjunctival 
MMC can be used in conjunction with the XEN gel implant to lessen scar reaction 
postoperatively (Sheybani et al. 2016). In that study, 89% of patients had an IOP 
reduction of ≥ 20% and 40% of patients were free of glaucoma medication after 
12 months of follow-up. Another study showed qualified success rates (IOP <18 
mmHg) of 80% in stand-alone surgery and 77% in a combination procedure of 
XEN gel implant and phacoemulsification after one year follow-up (Mansouri et al. 
2018). One retrospective study of 234 eyes showed a primary success rate of 66% 
with glaucoma medication allowed after mean follow-up of 8.5 months (Widder 
et al. 2018). However, to my present knowledge there are no long-term results of 
XEN gel implant available. 
The Trabectome (NeoMedix Inc., Tustin, CA, USA) is a device which uses 
electrocautery to remove a strip of tissue from the inner wall of Schlemm’s canal 
and trabecular meshwork (Minckler et al. 2005). The handpiece of the trabectome 
is inserted through a temporal corneal incision, and the trabecular meshwork is 
cauterized with the tip of the handpiece. During their procedure, a gonioscopic 
lens allows visualization of anterior chamber-angle structures. Mean IOP reduction 
after 2 years is 31% (Kaplowitz et al. 2016), and the use of glaucoma medications 
is reduced by 0.99 ±0.54. All bleb-related complications are avoided, since the 
37
trabectome allows a bleb-free procedure. The most common complications are 
hyphema, peripheral anterior synechiae, corneal injuries, and transient IOP spikes 
(Kaplowitz et al. 2016).
Another alternative to remove tissue from the trabecular meshwork is with the 
Kahook dual blade (Greenwood et al. 2017). It is an instrument with a curved tip 
and two blades (one on each side) placed behind the tip. It allows sharp cuts of 
trabecular meshwork tissue with visualization by a gonioscopic lens. Mean IOP 
reduction after 6 months follow-up was 26%, with blood reflux from collector 
canals seen in 39% of cases (Greenwood et al. 2017). 
Another option for bypassing the trabecular meshwork is the iStent (Glaukos 
Corporation, Laguna Hills, CA, USA), a titanium stent inserted with an injector 
through the peripheral corneal incision into Schlemm’s canal. While in place, it 
allows aqueous to bypass the trabecular meshwork. Postoperative IOP after 2 years 
decreased from 20.3 to 13.6 mmHg, but the amount of glaucoma medication in 
use remained unchanged (Ferguson et al. 2016). Two or three iStents can even be 
injected during the same procedure (Katz et al. 2015). 
Aqueous outflow from the anterior chamber directly to the suprachoroidal 
space can be achieved with a CyPass Micro-Stent (Alcon, Fort Worth, TX, USA), 
a 6.35mm long polyamide tube inserted through the corneal incision between 
the ciliary body and sclera with a gonioscopic lens and a guidewire. Postoperative 
IOP has been 16.4 mmHg after 12 months’ follow-up with a mean of 1.4 glaucoma 
medications in use (Garcia-Feijoo et al. 2015). However, 17% needed additional 
glaucoma surgery during their first postoperative year. 
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12 COMPLICATIONS OF GLAUCOMA SURGERY
12.1 Common complications of surgical treatment
Hypotony, IOP falling too low postoperatively, results from postoperative filtration 
becoming too strong. It is usually transient, and its duration may be from a few 
days to many months. The definition of hypotony varies: IOP <4 to <6 mmHg is 
usual (Bissig et al. 2008, Palanca-Capistrano et al. 2009, Anand et al. 2011). After 
glaucoma surgery, prolonged hypotony usually refers to low IOP on repetitive 
measurements on different days or low IOP lasting for several weeks (Bissig et al. 
2008, Cillino et al. 2008) or months (Anand et al. 2011). Hypotony is a serious 
complication of glaucoma surgery and can lead to problems in the fundus: hypotony 
maculopathy or choroidal detachment (Higashide et al. 2016); these can threaten 
vision.
If the postoperative aqueous outflow achieved is too strong compared to the 
aqueous production, the anterior chamber (AC) may become shallow. A shallow 
AC can dramatically reduce visual acuity in the immediate postoperative period 
and can lead to increased risk of hemorrhage into the anterior chamber.
The conjunctiva is opened during glaucoma surgery and then closed with sutures 
at the end of the operation. If these sutures are not closed carefully, aqueous 
may leak out of the surgical conjunctival wound, creating a possible migration 
route for extraocular bacteria. Later, the conjunctival filtration area may leak (bleb 
leak), which some surgeons consider a particular issue after trabeculectomy in 
conjunction with MMC.
With perforating glaucoma surgical procedures, the eye wall is penetrated. Some 
procedures may involve mechanical perforation of the peripheral iris: surgical 
iridotomy. Both of these may lead to postoperative bleeding into the anterior 
chamber (hyphema). Hyphemas can appear postoperatively even after non-
perforating surgery. Blood in the anterior chamber and bloody aqueous flowing 
into the bleb may increase the risk of postoperative scarring of the conjunctiva 
and bleb by promoting fibroblast activity (Lama & Fechtner 2003).
Choroidal effusion is characterized by fluid accumulating in the suprachoroidal 
space postoperatively. The fluid can be serous or hemorrhagic; these conditions are 
clinically called (serous) choroidal detachment and suprachoroidal hemorrhage, 
respectively. Serous choroidal detachment results when, after glaucoma surgery, 
IOP falls and a subsequent increase in transmural pressure is achieved in capillaries 
(Schrieber & Liu 2015). Suprachoroidal hemorrhage occurs when the posterior 
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ciliary artery ruptures (Chu & Green 1999) during or after surgery. Mild serous 
choroidal detachment is usually painless, but suprachoroidal hemorrhage can be 
associated with severe pain in the affected eye.
Choroidal effusion is usually diagnosed with a fundus examination: one to four 
convex areas of choroidal detachment can be seen, delineated by vortex veins. With 
ultrasonography, serous and hemorrhagic fluid can be evaluated; echo density is 
thicker when blood is present in the suprachoroidal space (Schrieber & Liu 2015). 
Treatment can be with topical steroids and cycloplegics when conjunctival leakage 
has been ruled out. Serous detachment usually resolves if hypotony is treated, with 
visual acuity increasing to its preoperative level. Suprachoroidal hemorrhage has 
a worse prognosis compared to serous choroidal detachment, and visual acuity 
usually decreases severely (Reynolds et al. 1993).
Hypotony can lead to folds in the posterior retina and macula. Folding may 
lead to distortion of photoreceptor cells, collapse of the scleral wall, shortening 
of axial length, and relative hyperopia. In hypotony, irregular astigmatism may 
increase, which may affect visual acuity of the affected eye even more (Costa & 
Arcieri 2007). Cystoid macular edema may be present because of alterations in 
vascular permeability (Kokame et al. 2001), but this is assumed to be less important 
to decrease in visual acuity (Costa & Arcieri 2007). Changes in lamina cribrosa 
structures may lead to papilloedema in association with hypotony maculopathy 
(Minckler & Bunt 1977). B-scan ultrasound and especially OCT are helpful in 
diagnosing hypotony maculopathy. In trabeculectomy, use of MMC may elevate 
risk of hypotony maculopathy, the incidence of which has been reported between 0 
and 20% (Costa & Arcieri 2007). Treatment of hypotony maculopathy is essentially 
the same as treatment of hypotony; the focus is upon an increase in IOP in order 
to reverse the inward bowing of the sclera. Treatment of hypotony and related 
complications includes suturing the conjunctiva or bleb if leakage occurs (Haynes 
& Alward 1999), injection of blood under the conjunctiva (Wise 1993), or closing 
the scleral flap tightly with sutures (Eha et al. 2008).
A functioning filtering bleb is essential for the success of penetrating and non-
penetrating glaucoma surgery. Usually a larger, diffuse bleb with limited vasculature 
is considered ideal postoperatively. The presentation of an encapsulated bleb 
(Tenons cyst) is different: it is localized, usually highly vascular and dome-shaped 
with a thick wall. The subconjunctival tenons capsule forms a cyst-like cavity. An 
encapsulated bleb may lead to elevated IOP. After limbal surgery, an encapsulated 
bleb may cause discomfort, or dellen formation. Encapsulated blebs can be treated 
conservatively (Costa et al. 1997), but sometimes needling is required (Ewing & 
Stamper 1990).
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Aqueous misdirection after intraocular surgery is characterized by elevation 
of IOP with subsequent anterior displacement of the iris and lens diaphragm. 
Its mechanism is not completely known, but the ciliary body, anterior hyaloid, 
and lens are involved (Ruben et al. 1997). As a result, aqueous produced by the 
ciliary body is directed posteriorly, with elevated or even low IOP (Greenfield et 
al. 1999). Symptoms may include decrease in vision, eye pain, and eye redness. 
Suprachoroidal hemorrhage, pupillary block glaucoma, and choroidal detachment 
need to be ruled out. Medical treatment includes mydriatics, lessening of aqueous 
production, and hyperosmotics (Simmons 1972). Surgically, anterior vitrectomy or 
pars plana vitrectomy with zonulectomy and iridotomy (Debrouwere et al. 2012) 
can be performed to re-establish a normal aqueous flow direction. 
After glaucoma surgery, cataract progression is faster. This is especially true 
with trabeculectomy (AGIS (Advanced Glaucoma Intervention Study) Investigators 
2001, Bindlish et al. 2002, Lim & Cha 2017), but also after tube surgery, cataract 
progresses at the same rate as after trabeculectomy (Gedde et al. 2012a). 
Postoperative inflammation and other complications are associated with cataract 
growth (AGIS (Advanced Glaucoma Intervention Study) Investigators 2001).
Astigmatic changes may occur after trabeculectomy (Hugkulstone 1991). The 
reason for these changes is unknown. Placement of the corneal flap and tight 
sutures (Hugkulstone 1991) and cautery (Rosen et al. 1992) have been proposed 
as the explanation. Use of MMC may induce less with-the-rule astigmatism after 
trabeculectomy (Hong et al. 1998). 
12.2 Intraoperative complications of deep sclerectomy
Intraoperatively, a tear in the TDM may occur. If it is small, and the anterior 
chamber is maintained, it is referred to as a microperforation and may go unnoticed 
during the operation. Even though microperforations are small, they can lead to 
hypotony during the first postoperative weeks. If a larger tear in the TDM occurs 
intraoperatively, aqueous flows rapidly through it, IOP decreases instantly, the 
anterior chamber becomes shallow, and even a flat anterior chamber may occur. 
When a large perforation of the TDM occurs, a surgical iridotomy will be needed 
in order to avoid iris incarceration into the large TDM opening. Alternatively, the 
procedure can be transformed to trabeculectomy (Karlen et al. 1999, Ollikainen 
et al. 2011).
The incidence of TDM perforations has been 1.4 to 5.7% (Karlen et al. 1999, 
Ollikainen et al. 2011), but this incidence seems to become lower with more 
experienced surgeons (Karlen et al. 1999). The incidence of intraoperative 
microperforation has been 13% (Ollikainen et al. 2011). 
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12.3 Early postoperative complications of deep sclerectomy
Deep sclerectomy, even though it is a non-penetrating technique, may lead to 
inflammation of the anterior chamber during the first postoperative days; this 
can be detectable in laser flare-cell measurement (Chiou et al. 1998a). One 
week postoperatively, inflammation settles into its preoperative state after deep 
sclerectomy, as opposed to four weeks after trabeculectomy (Chiou et al. 1998a). 
Postoperative inflammation promotes release of cytokines and fibroblast activity 
in the wound area. These can lead to granulation-tissue formation and eventually 
scarring and fibrosis of the wound area (Seibold et al. 2012).
Incidence of macular edema related to hypotony after deep sclerectomy has 
been reported at between 0 and 3.5% (Dahan & Drusedau 2000, Bissig et al. 2008).
During the first day or a few days after DS, the eye is very commonly hypotonous, 
but this is normally transient, and the IOP rises during the first weeks (Shaarawy et 
al. 2001). If the eye remains hypotonous after DS, a perforation or microperforation 
to the anterior chamber may have occurred during the operation. Ways to treat 
postoperative hypotony are several. Autologous blood can be injected under the 
conjunctiva near the flap to achieve stronger scar formation and a subsequent 
rise in IOP. The scleral flap can be partially or completely closed by sutures. Such 
closure can be achieved by suturing through conjunctiva (Shirato et al. 2004) or 
by first opening the conjunctiva and then suturing the scleral flap.
Prolonged hypotony can lead to choroidal detachment, but that usually resolves 
by itself if the hypotony is treated. Choroidal detachment is rare after DS, the 
incidence having been 0.5 to 7.6% (Bissig et al. 2008, Anand et al. 2011) in studies 
with larger patient populations. 
Detachment of the Descemet’s membrane after DS is a very rare complication. 
It has been reported a few times, with its highest incidence being 1.5% (Kozobolis 
et al. 2001, Ravinet et al. 2002, Anand et al. 2011). It occurs when the Descemet’s 
membrane detaches from the underlying corneal stroma, and fluid accumulates 
in this new space. Postoperatively, it can be diagnosed by a decrease in visual 
acuity and corneal opacification (Ravinet et al. 2002), if detachment progresses 
centrally to the pupillary area. The underlying reason has been suggested to be high 
intrableb pressure with a tenons cyst or trauma (Ravinet et al. 2002). Hemorrhagic 
Descemet’s membrane has also been reported (Kozobolis et al. 2001). Treatment 
is with intracameral injection of sulfur hexafluoride gas (Ravinet et al. 2002) or, 
if visual acuity remains good, with follow-up only (Kozobolis et al. 2001, Ravinet 
et al. 2002). After follow-up, visual acuity usually returns to its preoperative level 
(Kozobolis et al. 2001, Ravinet et al. 2002).
Hyphema, one of the major complications after trabeculectomy (Edmunds et al. 
2002, Stalmans et al. 2006), usually resolves by itself but can raise postoperative 
IOP and possibly worsen postoperative fibrosis. For this reason, hyphema is 
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considered a significant complication of glaucoma surgery. Incidence of hyphema 
after DS has been reported as between 2.6% and 21% (Kozobolis et al. 2002, Bissig 
et al. 2008, Cillino et al. 2008, Anand et al. 2011). A low incidence of hyphema 
can be explained by DS being initially a non-perforating technique, with the wall 
of the eye not being perforated during the procedure. Normally, no iridotomy is 
performed, as opposed to the procedure in trabeculectomy. Hyphema after DS can 
result from perforation of Descemet’s membrane and subsequent bleeding under 
the conjunctiva or blood flow from iris vessels or ciliary processes (Mendrinos et 
al. 2008). 
A postoperative wound leak results from inadequate closure of the conjunctiva 
after DS, with its incidence being 3.3 to 8.6% (Kozobolis et al. 2002, Bissig et al. 
2008, Anand et al. 2011). A postoperative wound leak is diagnosed by a positive 
Seidel test. Wound leaks after DS offer a possible route for bacterial invasion of 
the surgical bleb and subsequent blebitis or possibly endophthalmitis. A wound 
leak can be treated with a therapeutic contact lens, surgical resuturation of the 
conjunctiva (with possible patching with a conjunctival autograft) (Ollikainen et 
al. 2011), or with observation only. 
Blebitis is a bacterial infection of the filtration area under the conjunctiva; the 
cause is microbial invasion, possibly after a wound leak. Postoperative blebitis is 
rare after DS with incidence of only 0 to 1% (Bissig et al. 2008, Anand et al. 2011).
Endophthalmitis is a bacterial infection inside the globe: in the anterior chamber, 
posterior chamber, or vitreous cavity. 
The Descemet’s membrane, during DS, is left intact. This forms an 
anatomical barrier between subconjunctival and intraocular spaces. One reported 
endophthalmitis after DS showed an intraoperative Descemet’s membrane tear 
(Anand et al. 2011), but to the best of my knowledge no other study has reported 
postoperative endophthalmitis (Kozobolis et al. 2002, Bissig et al. 2008, Ollikainen 
et al. 2011). Although postoperative endophthalmitis is rare after DS, no statistical 
difference in endophthalmitis incidence can be found between DS and penetrating 
glaucoma surgery (Ang et al. 2010).
Postoperatively, the iris can adhere to the Descemet’s window. This can lead 
to a dramatic rise in IOP, sometimes to higher than the preoperative level. It is 
considered to occur because of an unnoticed microperforation or perforation of 
Descemet’s membrane during the primary surgery. Another time of occurrence is 
after GP, when a YAG laser hole is made in the Descemet’s membrane to increase 
the ouflow of anterior chamber fluid.
On both of these occasions, ouflow of anterior chamber fluid draws part of 
the iris into the hole in the Descemet’s membrane. The iris closes the hole in the 
Descemet’s membrane and IOP begins to rise because outflow decreases. 
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12.4 Late postoperative complications of deep sclerectomy
Conjunctival and episcleral scarring postoperatively can lead to fibrosis of the 
surgical bleb. Signs are elevated IOP with diffuse conjunctival injection in the 
early phase (Mendrinos et al. 2008). Later, the bleb can appear encapsulated, and 
the wall can be thickened. These changes lead to a decrease in filtration under 
the conjunctiva with a subsequent rise in IOP, and, if continued, lead to surgical 
failure if filtration stops. 
Intraoperative antimetabolites may prevent or lessen bleb fibrosis. Bleb fibrosis 
after DS has been 11.4 to 16.7% (Kozobolis et al. 2002, Bissig et al. 2008).
Cataract progression has also been reported after DS. After DS, 23% of eyes 
needed a cataract operation after 3 years of follow-up (Ollikainen et al. 2011) and rate 
of cataract progression appears to be lower compared to that with trabeculectomy, 
with 20% needing a cataract operation during first postoperative year (Edmunds 
et al. 2002). This is thought to occur because DS is an initially non-perforating 
procedure, the anterior chamber is not entered with surgical instruments, and no 
iridectomy is made. 
DS seems to have only a small effect on corneal curvature. After the combination 
procedure of DS and phacoemulsification, the average amount of keratometric 
astigmatism change has been 0.18D (Corcostegui et al. 2004). Non-penetrating 
glaucoma surgery seems to induce fewer corneal astigmatic changes than does 
trabeculectomy (Egrilmez et al. 2004).
DS induces loss of corneal endothelial cells postoperatively. There is only one 
comparative study concerning endothelial cell loss after DS and trabeculectomy 
without MMC (Arnavielle et al. 2007). In that study endothelial cell loss was 4.5% 
during the first postoperative year after DS, compared to 9.6% after trabeculectomy.
Effect of DS on axial length (AL) is not known. AL is decreased after 
trabeculectomy by 0.26 to 0.32 mm when IOP is lowered (Saeedi et al. 2014, Usui et 
al. 2013). The choroidea is thickened when IOP is lowered with trabeculectomy; half 
of the optically measured AL decrease was actually due to an increase in choroideal 
thickness (Saeedi et al. 2014). Reported postoperative complications of two DS 
studies (Bissig et al. 2008, Anand et al. 2011) and Tube versus trabeculectomy 
study (Gedde et al. 2012a) are summarized in Tables 1. and 2.
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Table 1. Early postoperative complications in two DS studies (Anand et al 2011 and Bissig et al.2016) 
and Tube versus trabe study (Gedde et al. 2012). Numbers in percentage of eyes affected.
Tube = subgroup of Baerveldt shunt in Tube versus trabeculectomy study; Trabe + MMC = subgroup 
of Trabeculectomy with MMC in Tube versus trabeculectomy study
Table 2.  Late postoperative complications in two DS studies (Anand et al 2011 and Bissig et al. 2008) 
and Tube versus trabe study (Gedde et al. 2012). Definitions of bleb configuration and ocular fundus 
changes may exist between studies. Numbers in percentage of eyes affected.
Tube = subgroup of Baerveldt shunt in Tube versus trabeculectomy study; Trabe + MMC = subgroup 
of Trabeculectomy with MMC in Tube versus trabeculectomy study
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13 ANTIFIBROTICS
Postoperative bleb fibrosis is one of the most important reasons for failure of 
glaucoma surgery during the postoperative period. Antifibrotics can be useful 
in avoiding excessive postoperative fibrosis. The most commonly used are 
Mitomycin-C (MMC) and 5-Fluorouracil (5-FU). 
13.1 Mitomycin-C
Mitomycin-C (MMC) is an antibiotic agent with an antiproliferative function 
affecting both fibroblasts and endothelial cells (Smith et al. 1994). It cross-links 
DNA, inhibits protein synthesis, and affects all phases of the cell cycle (Lama & 
Fechtner 2003). In glaucoma surgery, MMC prevents scar formation and enhances 
bleb survival. MMC is a much more potent agent than 5-Fluorouracil (5-FU) (Smith 
et al. 1994) and can be instilled intraoperatively or during the postoperative period 
(Liu et al. 2016). MMC use in trabeculectomy was published in 1990 (Chen et al. 
1990), and it has become widely used in glaucoma filtration surgery.
Intraoperatively, polyvinylalcohol sponges are soaked in MMC and inserted 
under the conjunctiva and scleral flap for 1 to 4 minutes. Then the sponges are 
removed, and the MMC is carefully washed away with balanced salt solution (BSS). 
The concentration of MMC can vary, with concentrations usually being 0.02 mg/
ml to 0.4 mg/ml (Anand 2011, Mansouri et al. 2011).
Postoperatively MMC can be injected under the conjunctiva with needling 
performed subsequently when needed.
MMC has been widely used in deep sclerectomy, achieving good IOP control 
postoperatively (Kozobolis et al. 2002, Anand et al. 2011, Guedes et al. 2011, 
Ollikainen et al. 2011, Mercieca et al. 2015). 
The number of studies comparing DS with and without MMC are limited. In 
one study (Kozobolis et al. 2002), MMC was found to enhance the IOP-lowering 
effect of DS with a rate of adverse effects comparable to that in DS without MMC. 
Postoperative IOP was 15.96 mmHg with MMC, compared to 18.71 without. MMC 
did not raise the risk of postoperative complications. 
In another study, MMC used in DS did not affect the qualified success rate 
postoperatively: 72.4%, compared to 61.4% without MMC (Mercieca et al. 2015). 
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When comparing trabeculectomy with and without intraoperative MMC, results 
have been controversial. In two studies (Cohen et al. 1996, Carlson et al. 1997), 
MMC use resulted in better IOP control postoperatively. However, in another study, 
no difference in surgical success appeared when comparing surgical results after 
trabeculectomy with or without use of MMC (Shin et al. 1998).
Since MMC has a potent wound healing inhibition effect, adverse effects have 
also emerged. 
Late-onset infections after trabeculectomy have been more common after 
MMC use (Jampel et al. 2001). In one study analyzing eyes with postoperative 
endophthalmitis, 67% had been operated on with MMC (Song et al. 2002). 
Hypotony maculopathy has also been associated with MMC use in trabeculectomy 
(Costa et al. 1993, Suner et al. 1997). Endothelial-cell loss after trabeculectomy with 
MMC has been 9.5% during the first three months postoperatively, but after that, 
further cell loss did not occur (Storr-Paulsen et al. 2008). Reports also involve 
scleritis (Fourman 1995) and scleromalacia (Akova et al. 1999) after trabeculectomy 
augmented with MMC.
13.2 5-fluorouracil
5-fluorouracil (5-FU) functions as an antimetabolite by competitively inhibiting 
further synthesis of thymine nucleotides. This leads to cessation of DNA synthesis, 
which leads to cell death (Lama & Fechtner 2003). Exposure to 5-FU leads to 
inhibition of tenon capsule fibroblast proliferation (Gressel et al. 1984, Khaw et 
al. 1992) and to inhibition of the contraction of collagen (Occleston et al. 1994). 
In conjunction with deep sclerectomy, 5-FU is normally administered in one or 
several postoperative injections when IOP is elevated and postoperative scarring 
or vascularisation of conjunctiva is present (Ambresin et al. 2002, Khairy et al. 
2006, Bissig et al. 2008). In one study’s postoperative period after DS, 24.5% of 
eyes needed at least one subconjunctival 5-FU injection, with 4.9% of eyes having 
a needling procedure with 5-FU (Bissig et al. 2008). Alternatively, sponges soaked 
with 5-FU can be instilled under the conjunctiva for up to 5 minutes, after which 
they are removed and the 5-FU washed away (Singh et al. 2000, Joshi et al. 2005).
No randomized studies concern the IOP-lowering effect of 5-FU with DS. With 
trabeculectomy, postoperative IOP has been lower after 5-FU use: 12.0 vs. 16.8 
mmHg, after 20 month’s follow-up (Goldenfeld et al. 1994). Side-effects were the 
same as with the non-5-FU group, except that corneal punctate keratopathy was 
more common. 
Side-effects of 5-FU with trabeculectomy have included corneal toxicity (Shapiro 
et al. 1985) and increased risk of endophthalmitis (Wolner et al. 1991).
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AIMS OF THE STUDY
(I) 
To study retrospectively the pressure-lowering effect of DS in NTG patients (I). 
How low an IOP can be reached by DS with or without MMC. To find possible 
complications of DS when low IOP is targeted.
(II) 
To study prospectively the intraocular pressure-lowering effect of DS in NTG 
patients (II) until one year postoperatively.
To compare the effect of DS with and without MMC on postoperative IOP, on 
surgical success, and on adverse effects during the first postoperative year.
(III)
To study the long-term IOP-lowering effect of DS with and without MMC in NTG 
patients.  
To compare DS with and without MMC on surgical success and adverse effects 
after long-term follow-up.
(IV)
To study and compare, retrospectively, the pressure-lowering effect of DS in POAG 
and EXG patients (IV). 
To find any preoperative, intraoperative, or early postoperative factors related to 
surgical success.
(V)
To study prospectively the effect of IOP-lowering with DS on visual acuity in the 
early postoperative period (V).
To study the effect of DS on macular structures, and on corneal curvature, and 
corneal-shape indices in the early postoperative period.
48
MATERIAL AND METHODS
All patients were operated on in Helsinki University Central Hospital by glaucoma 
surgeons. Deep sclerectomy was performed as follows: the flap of the conjunctiva 
was performed superiorly, superolaterally, or superotemporally with its base in 
fornix. Superficial flap was rectangular with a thickness of one-third of the sclera. 
The scleral flap was cut anteriorly until the cornea was reached. If MMC was 
used, polyvinyl alcohol sponges were impregnated in it and then were introduced 
under the conjunctiva. The MMC was washed away with a balanced salt solution. 
A rectangular deep flap was created with its anterior edge reaching the cornea in 
order to achieve a trabeculo-Descemet’s window of adequate size while separating 
the corneal stroma and the Descemet’s membrane. The central wall of Schlemm’s 
canal was carefully removed and the deep flap was completely excised. The collagen 
implant in use was Aquaflow® (Staar Surgical, Nidau, Switzerland), fixed to the 
stromal bed with one 10-0 polyamide (Ethilon®, Ethicon Inc, Somerville, NJ, 
USA) suture in order to keep the scleral pocket open during the first postoperative 
months. The superficial flap was loosely closed with 10-0 nylon sutures. Closure 
of the conjunctiva was performed by continuous or interrupted sutures or both, 
with 9-0 polyglactin (Vicryl®, Johnson & Johnson, St-Stevens-Woluwe, Belgium). 
A triamcinolone injection was given subconjunctivally. 
The definition of glaucoma was optic neuropathy with visual field defect and 
optic nerve head presenting with common glaucomatous morphologic changes 
in the absence of other ocular or congenital diseases. Open-angle glaucoma 
was considered when glaucoma patients had open angles in examination with a 
gonioscopic lens.
POAG was defined when open-angle glaucoma patients had IOP ≥ 22 mmHg, 
and no signs of secondary glaucoma. EXG was considered, if exfoliation material 
was seen in open-angle glaucoma patients in the anterior capsule or pupil border 
after pupil dilatation. NTG was considered when patients with open-angle glaucoma 
always had an IOP of 21 mmHg or lower (one to two measurements between 22 
and 24 mmHg allowed) and no signs of secondary glaucoma (such as exfoliation 
material or pigment deposits). IOP was measured with Goldmann applanation 
tonometer.
Normal distribution of samples was tested with Shapiro-Wilk or Kolmogorov-
Smirnov tests. Summary statistics were presented as mean (±standard deviation, 
SD) when normal distribution was found. When normality assumption did not 
hold, median and range were used as summary statistics. The Wilcoxon signed 
ranks test was used to test comparisons in paired samples. The Mann-Whitney test 
was used to test non-paired samples. When samples were normally distributed, 
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Student’s t-test was used to compare equality of means. Chi-squared test and 
Fisher’s exact test (Study III) were used to test equality of the proportions. Survival 
analysis in Study III was performed with the Mantel-Cox test when comparing 
MMC and non-MMC groups. Success probabilities in Study IV were assessed with 
Kaplan-Meier estimators. The relative effect of fixed and time-varying explanatory 
variables on hazard of failing was modeled with an extended Cox-model (Study 
IV). Statistical significance level was set at p= 0.05. In studies II and III, sample 
size was calculated with alpha error of 5% and beta error 50%. In Study IV sample 
size was calculated with alpha error 5% and beta error 10%.
(I)
I analyzed 21 eyes of 18 consecutive NTG patients (16 women, two men). Patients 
underwent DS in Helsinki University Central Hospital between 2004 and 2007. 
Indication for surgery was progression of visual field loss, an IOP considered too 
high despite medication or intolerance to topical glaucoma medication. DS was 
performed superiorly, superonasally, or superotemporally. All but one patient 
received MMC (0.4mg/ml) soaked polyvinylalcohol sponges for 3 minutes under 
the conjunctiva. In three eyes DS was combined with phacoemulsification from 
a temporal wound and implantation of an intraocular lens. Follow-up visits were 
scheduled for 1 day, 1 week, 2 weeks, and 4 weeks postoperatively. After 4 weeks, 
follow-up was carried out either in our hospital or by local ophthalmologists. If 
IOP was considered too high during follow-up, GP was performed. I reported 
success rates at three IOP levels: 20%, 25%, and 30% reduction. Success was 
considered complete if IOP reduction was achieved without glaucoma medication, 
and a qualified success if glaucoma medication was needed
(II and III)
We studied 37 eyes of 37 patients (29 women, 8 men) in these prospective 
randomized controlled studies. Patients were consecutive NTG patients scheduled 
for DS in Helsinki University Central Hospital between 2007 and 2009. DS was 
performed superiorly in all patients. Patients were randomized with respect to the 
use of intraoperative MMC. The group operated on with intraoperative MMC had 
15 patients and 22 patients were operated on without MMC (Table 3). 
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Table 3. Baseline characteristics of patients. Data are presented as mean ± SD.








MMC = mitomycin-C used with operation, non-MMC = mitomycin-C not used, P = p-value, IOP = intra-
ocular pressure, CCT = central corneal thickness, MD = mean defect in visual field, CDR = cup-to-disc 
ratio, LTP = lasertrabeculoplasty, SLT = selective laser trabeculoplasty. 
 
 
 MMC (n=15) non-MMC (n=22) P 
Age [years] 65 ± 5 62 ± 8 0.22 
Follow-up [months] 12.3 ± 0.5 12.2 ± 0.4 0.31 
Sex 13 women 16 women 0.31 
IOP [mmHg] 15.2 ± 2.8 15.1 ± 2.9 0.92 
CCT [µm] 516 ± 33 515 ± 47 0.94 
Number of glaucoma medications 2.2 ± 0.8 2.6 ± 1.0 0.27 
MD [dB] 9.4 ± 7.3 9.9 ± 5.5 0.80 
CDR 0.84 ± 0.13 0.80 ± 0.10 0.37 
Previous phacoemulsification 1 3 0.42 
Previous LTP 4 1 0.053 
Previous SLT 2 1 0.336 
 MMC = mitomycin-C used with operation, non-MMC = mitomycin-C not used, P = p-value, IOP = intra-
ocular pressure, CCT = central corneal thick ess, MD = mean defect in visual field, CDR = cup-to-disc 
ratio, LTP = lasertrabeculoplasty, SLT = selective laser trabeculoplasty.
MMC was used intraoperatively in the same way as in study (I). All patients received 
a collagen implant during the operation. The indication for surgery was progression 
of visual field loss (32 eyes) and IOP considered too high (5 eyes).
During the follow-up period, if IOP was considered too high, GP was performed 
at least one month postoperatively. Topical glaucoma medication was begun if 
GP had been performed and IOP remained too high. Needling with or without 
antimetabolites was performed when necessary.
Follow-up visits were scheduled 1 day, 1, 2, and 4 weeks, and 3, 6, and 12 
months postoperatively (Study II). Additional follow-up visits 3, 5, and 6 to 9 
years postoperatively were included (Study III). The outcome was considered a 
complete success if IOP was lowered by 25%, IOP was >4 mmHg, and no glaucoma 
medication was required. If medication was necessary to achieve the same limits, 
the operation was considered a qualified success.
(IV)
I analyzed retrospectively 235 eyes of 198 patients (138 women), who were the first 
consecutive patients operated on in Helsinki University Central Hospital with DS for 
either POAG or EXG between 2004 and 2006. I included only eyes with untreated 
IOP ≥ 22 mm Hg and an open angle in gonioscopy. If exfoliation material was 
present during examination, the eye was included in the EXG group (108 eyes). If no 
exfoliation material was present, the eye went into the POAG group (127 eyes). All 
other glaucoma subtypes were excluded. Follow-up visits were initially scheduled 
for 1 day, 1 week, 2 weeks, and 4 weeks postoperatively. After that, follow-up was 
carried out in our hospital or by local independent ophthalmologists.
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Complete success was defined as an IOP between 4 and 17 mmHg without 
medication, and qualified success as an IOP between 4 and 17 mmHg with 
glaucoma medication allowed. 1-week success was defined as an IOP between 2 
and 14 mmHg one week postoperatively without medication. We studied different 
factors affecting the outcome of surgery by a Cox regression model in which we 
included as explanatory variables patient age, glaucoma subtype, preoperative 
IOP, number of preoperative glaucoma medications, any previous ocular surgery, 
surgeon’s experience, use of intraoperative MMC, and 1-week success. The effect of 
the surgeon’s experience on surgery outcome was examined by giving the patient 
a number indicating the number of DSs performed by that surgeon during his/
her career (the number “4” for the surgeon’s fourth operation, “21” for the 21st 
operation).
(V)
I analyzed 35 eyes of 35 patients who underwent surgery with DS for POAG, 
EXG, or NTG. Each was examined preoperatively, one week, two weeks, and four 
weeks postoperatively. With every examination, I performed subjective refraction, 
IOP measurement by Goldmann applanation tonometer, and an ophthalmologic 
examination. Anterior chamber depth (ACD) and axial length (AL) were measured 
by IOL-master (Carl-Zeiss Meditec AG, Jena, Germany). Corneal shape was 
evaluated by a corneal Galilei Dual Scheimpflug Analyzer (SIS Surgical Instrument 
Systems AG, Biel, Switzerland). The corneal Scheimpflug was analyzed by a cornea 
specialist. I measured macular volume and foveal thickness using Stratus OCT 
(Optical Coherence Tomography, Stratus OCT Model 3000, Carl Zeiss Meditec 
Inc., Dublin, CA, USA). OCT measurements were analyzed by a retina specialist 




After a median 13 months’ follow-up, IOP was significantly decreased to 10.5 mmHg 
(4-15). Median IOP reduction was 37% (12-78). Complete success at a 20%, 25%, 
and 30% reduction in IOP was achieved in 67%, 62%, and 52% of eyes. Qualified 
success was achieved in 71%, 67%, and 52% respectively. One patient needed a 
re-operation after 5 months, and was included in the success analysis as a failure.
Median glaucoma medication was reduced from 3 (0-4) preoperatively to 0 
(0-3, p<0.001) postoperatively. By the last follow-up visit, GP had been performed 
on 10 eyes (48%). Among these eyes, IOP decreased from 16 mmHg (12-19) prior 
to GP to 12 mmHg (6-19) after GP. Intraoperative complications were tearing 
of the conjunctiva (three eyes) and microperforation (one eye). Postoperative 
complications were loss of two or more Snellen lines of visual acuity in three eyes 
and resuturing of the conjunctiva in three eyes. Hypotony (IOP <4 mmHg) was 
found in nine eyes (43%) one week, and in two eyes (10%) 4 weeks postoperatively. 
No eyes showed choroidal detachment, shallow anterior chamber, or hypotony 
maculopathy.
(II and III)
Initially 37 patients were included in the study and continued follow-up until one 
year (Study II, Table 3). After that, 3 patients (8%) dropped out; 13 patients in 
the MMC group and 21 in the non-MMC group had complete follow-up of 6 to 9 
years (Study III). IOP decreased significantly in the MMC group from 15.2 mmHg 
(2.8) to 5.9 (3.1), p<0.001 one month postoperatively. Postoperatively, after 3, 6, 
and 12 months, IOP decreased to a respective 7.6 mmHg (3.7), p<0.001; 8.0 (3.1), 
p<0.001; and 9.3 (2.7), p<0.001. IOP was 9 mmHg (2-13), p=0.002, at the last 
follow-up visit 6 to 9 years postoperatively (Table 4). 
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In the non-MMC group, IOP decreased from 15.1 mmHg (2.9) to 11.0 (3.6), p<0.001 
one month postoperatively; 3, 6 and 12 months postoperatively IOP was a respective 
13.1 (4.3), p=0.10; 10.8 (3.3), p<0.001; and 11.8 (2.0), p<0.001. IOP was 10 mmHg 
(5-13), p<0.001, at the last follow-up visit. IOP was lower in the MMC group until 
5 years postoperatively, with no difference in IOP thereafter between groups. 95% 
confidence interval of IOP one year postoperatively was 7.8 to 10.8 mmHg in the 
MMC group and 10.9 to 12.7 mmHg in the non-MMC group. After 3, 5 and 6-9 
years, the 95% confidence intervals of IOP were 9.5 to 12.5, 9.0 to 12.3, and 6.3 
to 10.6 mmHg in the MMC group and 10.8 to 13.2, 11.6 to 14.0, and 8.7 to 10.8 
mmHg in the non-MMC group (unpublished). As for surgical success, we found no 
difference between groups at any point in time. Total success was achieved in the 
MMC-group in 10 of the 15 eyes (67%), and in the non-MMC group in 9 of the 22 
eyes (41%) in (p=0.12) after 12 months (Study II). After 6 to 9 years of follow-up, 
complete success in both groups combined was 50%, and qualified success was 








GP was performed in 47% of eyes in the MMC group and 73% in the non-MMC 
group during the first postoperative year (Study II), and GP rate increased to 87% 
and 100% after 6 to 9 years follow-up (Study III) with no difference between groups. 
Iris incarceration was encountered equally, 27% of eyes in the MMC group and 36% 
in the non-MMC group (p=0.64), all but one were treated with laser iridoplasty.
One month postoperatively, 4 eyes (27%) in the MMC group had hypotony (IOP 
< 4mmHg); 3 and 6 months postoperatively, three and two eyes had hypotony. 
After 12 months, none of the eyes had hypotony (Table 5). 
Table 5. Intra- or postoperative complicationsTable 5. Intra- or postoperative complications 
 MMC (n=15) non-MMC (n=22) p-value 
Hypotony 1 months 4 0 0.010 
                 3 months 3 0 0.029 
                 6 months 2 0 0.078 
                12 months 0 0  
Cystoid maculopathy 1 0 0.22 
Loss of ≥ 3 lines of visual acuity 2 1 0.34 
Microperforation 1 0 0.22 
Dellen 1 1 0.78 
Needling 2 4 0.69 
Resuturation of conjunctiva 1 5 0.19 
The non-MMC group showed no postoperative hypotony. Two eyes in the MMC 
group had IOP between 2 to 4 mmHg, both with visual acuity of 1.0 in Snellen 
after 6 to 9 years of follow-up. 
Four eyes had a BCVA reduction of 2 or more Snellen lines after 6 to 9 years 
of follow-up. Two eyes developed cataracts, one eye had macular degeneration, 
and one eye developed diabetic maculopathy.
Twelve months postoperatively, 12 eyes (80%) in the MMC group and 15 (68%) 
in the non-MMC group needed no glaucoma medication (p=0.427), the number of 
glaucoma medications in use was reduced in both groups throughout follow-up, 
and no difference existed between groups. Conjunctival resuturation was necessary 
for one eye in the MMC group and five eyes (23%) in the non-MMC group. 
Needling was performed in two eyes (13%) in the MMC group and four eyes 
(18%) in the non-MMC group during the first year. This trend continued, the 
median number of needlings in the MMC group being 0 (0-2) compared to the 
non-MMC group’s one (0-5, p=0.08) until the end of follow-up. When needling 
was necessary, the trend was towards more repetitions in the non-MMC group. 
Initially 14 phakic eyes were in MMC group and 19 in the non-MMC group, with 
a cataract operation performed in six (43%) and in six (32%, p=0.42) respectively.
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The rate of serious postoperative complications was low, with no cases of 
choroidal effusion, hypotony maculopathy, shallow anterior chamber, hyphema, 
endophthalmitis, late bleb leakage, blebitis or malignant glaucoma encountered.
(IV)
A total of 56 eyes had a follow-up of less than 12 months. These were included 
in the Cox regression model, but were excluded from other analysis of results. A 
total of 179 eyes (97 POAG and 82 EXG) had a follow-up of at least 12 months; 
mean follow-up was 38 (18) months, and between groups no difference emerged 
in duration of follow-up (p=0.303). MMC was used in 32 eyes (33%) with POAG, 
and in 22 eyes (27%) with EXG (p=0.37).
Preoperatively, IOP was lower in the POAG group, 22.6 mmHg (SD 5.1), than 
in the EXG group, 25.5 (6.5) (p=0.001). In the POAG group, IOP decreased to 16.8 
mmHg (7.5) (p<0.001) and in the EXG group to 16.5 (7.8) (p<0.001) (Table 6). 
Table 6. IOP, qualified and complete success, GP, and medication after the last visit of patients with at 
least 12 months` follow-up presented as mean (SD)
 
Table 6. IOP, qualified and complete success, GP, and medication after the last visit of patients with at 




n, number of eyes; IOP, intraocular pressure; PRE, preoperatively; POST, postoperatively; GP, 
goniopuncture; GP time, time between surgery and postoperative goniopuncture in months; 
Medication, number of glaucoma medications 
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 0.001 0.80 0.54 0.62 0.011 0.48 0.31 0.48 
 n, number of eyes; IOP, intraocular pressure; PRE, preoperatively; POST, postoperatively; GP, 
go iopunctur ; GP time, time betwe n surgery and postoperative goniopuncture in months; 
Medication, number of glaucoma medications
Postoperative IOP was the same between groups (p=0.80), but IOP reduction was 
greater in the EXG group than in the POAG group (9.0 mmHg vs. 5.8 mmHg) 
(p=0.023).
Complete success was achieved in 46% of eyes in the POAG group and in 
43% in the EXG group (p=0.62), and qualified success in 70% in the POAG and 
66% of eyes in the EXG groups (p=0.54). GP was more commonly performed in 
the EXG group (82%), than in POAG group (64%) (p=0.011). Reoperations were 
more common in the EXG group (24%), than in POAG group (12%) (p=0.037). 
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We studied the effect of explanatory variables on the complete and qualified 
success with Cox regression modeling. A one-week success lowered the hazard rate 
of losing complete success by 34% (p=0.031) and losing qualified success by 54% 
(p=0.004). We found no other factors to be related significantly to complete or 
qualified success. Surgeons’ experience in DS had no effect on achieving complete 
or qualified success. Patients were operated on by eight surgeons; the median 
number of operations was 32, with the range from 1 to 96 (unpublished).
(V)
IOP decreased from a preoperative 20.8 mmHg (5.1) to 8.8 (7.3) (p<0.001) after one 
week, to 9.9 (6.5) (p<0.001) after 2 weeks, and 12.8 (5.8) (p<0.001) after 4 weeks 
following the operation. BCVA changed from a preoperative 0.14 Logmar (0.12) to 
0.22 (0.20) (p=0.006) in one week, and to 0.19 (0.15) (p=0.011) in 2 weeks after 
the operation. BCVA returned to 0.17 (0.18) (p=0.28) 4 weeks postoperatively. Axial 
length decreased from 24.12 mm (1.81) preoperatively to 23.96 (1.81) (p<0.001) 
at one week, to 23.96 (1.82) (p<0.001) at 2 weeks, and to 24.02 (1.81) at 4 weeks 
postoperatively (Table 7). 
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TABLE 7. Parameters before and after deep sclerectomy. Results as mean (SD). P as compared to 
pre-operative values.
TABLE 7. Parameters before and after deep sclerectomy. Results as mean (SD). P as 
compared to pre-operative values. 
 
 PRE 1 WEEK P 2 WEEKS P 4 WEEKS P 









































44.6 (1.6) 44.9 (1.5) 0.007 44.8 (1.7) 0.06 44.9 (1.5) 0.022 
SIM K MIN 43.7 (1.6) 43.7 (1.5) 0.58 43.7 (1.5) 0.50 43.9 (1.4) 0.08 
SIM K MIN 
AXIS 
94 (49) 94 (51) 0.81 99 (56) 0.77 101 (45) 0.33 
ACP 44.3 (1.6) 44.4 (1.5) 0.029 44.3 (1.5) 0.41 44.5 (1.5) 0.014 
CCT 547 (25) 540 (29) 0.003 540 (27) 0.002 541 (24) 0.001 



















3/33, (9) 2/31, (7) >0.99 3/31, (10) >0.99 3/34, (9) >0.99 
 
PRE = Pre-operative values; IOP = Intraocular pressure; BCVA = Best corrected visual 
acuity; AL = Axial length in mm; ACD = Anterior chamber depth in mm; SPH EQUIV = 
Spherical equivalence; SIM K MAX = Steeper simulated K-value in diopters; SIM K MIN = 
Flatter simulated K-value in diopters; SIM K MIN AXIS = Axis of flatter axis in degrees; 
ACP = Average corneal power in diopters; CCT = Central corneal thickness in µm; MAC 
VOL = Central macular volume in mm³; FOV THICK = Foveal thickness in µm 
 PRE = Pre-operative values; IOP = Intraocular pressure; BCVA = Best corrected visual acuity; AL = Axial 
length in mm; ACD = Anterior chamber depth in mm; SPH EQUIV = Spherical equivalence; SIM K MAX 
= Steeper simulated K-value in diopters; SIM K MIN = Flatter simulated K-value in diopters; SIM K MIN 
AXIS = Axis of flatter axis in degrees; ACP = Average corneal power in diopters; CCT = Central corneal 
thickness in μm; MAC VOL = Central macular volume in mm³; FOV THICK = Foveal thickness in μm
A steeper corneal meridian changed from 44.6 D (1.6) preoperatively to 44.9 (1.5) 
(p=0.007) at one week, and to 44.9 (1.5) (p=0.022) 4 wee s postoperatively. The 
postoperative 95% confidence interval of steeper meridian varied between 44.23 
D to 45.47 D (unpublished). Average corneal power changed from 44.3 D (1.6) 
preoperatively to 44.4 (1.5) (p=0.029) at one week, and to 44.5 (1.5) (p=0.014) at 
4 weeks postoperatively. Central corneal thickness decreased from 547 um (25) 
preoperatively to 540 (29) (p=0.003) at one week, to 540 (27) (p=0.002) at 2 
weeks, and to 541 (24) (p=0.001) at 4 weeks postoperatively. The postoperative 
95% confidence interval of central corneal thickness varied between 530 and 550 
um (unpublished). Macular volume, foveal thickness, macular folds, and macular 
edema showed no change postoperatively. Four patients had macular folds in OCT 
measurement in association with hypotony after 2 weeks and two of these persisted 
until 4 weeks with visual acuities of 0.9 in Snellen lines.
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DISCUSSION
1 PATIENTS AND METHODS
Study I was retrospective, conducted to gain information as to how low an IOP can 
be reached with DS, which was a relatively new method in our hospital in 2007. 
I had only 18 patients and 21 eyes in this study, and follow-up was 12 months. 
These were the first patients operated on with DS in our hospital. Experience with 
Study I helped us in planning Study II.
Study II was prospective and randomized. This type of study was ideal for 
comparing two treatment methods: DS with or without MMC. We included only 
patients with low preoperative IOP, and our number of patients was relatively 
low, only 37. Few patients fulfill our criteria. We included, however, all eligible 
patients in our hospital’s department of glaucoma surgery over two and half years. 
The follow-up time was one year. 
Study III was a follow-up for the patients of Study II. It carried on until 6 to 9 
years postoperatively. Our dropout rate in Study III was low, only three patients 
were lost to follow-up; two discontinued study visits, and one died. In other studies, 
dropout rates have been higher (Bissig et al. 2008, Anand et al. 2011).
Definition of NTG was based on IOP measurements without consideration of 
vascular or systemic factors. One or two measurements of IOP between 22 and 
24 were allowed if all other IOP measurements were 21 mmHg or below (11 eyes). 
Although NTG features include peak IOP under 21 mmHg without treatment, these 
patients were included in the study. This definition may be challenged, but purpose 
was to find the IOP-lowering effect of DS when preoperative IOP is already low. 
The aim of the study was to find the IOP-lowering effect of DS when aiming 
for low postoperative IOP. Another aim was to find possible additional benefits 
of MMC use. No visual field measurements were studied and direct conclusions 
on preventing visual field loss on these patients cannot be made on the basis of 
my study. In order to be able to find differences in visual field defect progression, 
the study design would have to have been different, and a control group of non-
operated patients would have been needed. More frequent postoperative control 
visits with visual field testing would have been needed. My study aimed in studying 
IOP lowering with DS, since it has been beneficial in NTG patients.
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Study IV was retrospective, with POAG and EXG patients. These were the first 
POAG and EXG patients operated on with DS in our hospital. Being retrospective, 
its follow-up time varied. We included all patients in the Cox regression model, but 
we excluded patients with less than one year follow-up from final results concerning 
IOP. When patients with shorter follow-up were excluded, mean follow-up time 
was 38 months. After exclusion, I had 97 eyes in the POAG and 82 in the EXG 
groups, which is, to my knowledge, the largest number of EXG eyes in any peer-
reviewed study. 
Study V was prospective, with 35 patients and 35 eyes and a 3-month follow-up. 
An OCT analysis of the macula was carried out by a retina specialist in a masked 
fashion. During the immediate postoperative period, patients had difficulties 
focusing during OCT measurement, which may have been affected by their 
glaucomatous visual field defect. I had no equipment to study the thickness of 
the choroid, which would have been a very interesting topic. Corneal topographic 
measurements were sometimes difficult to perform and analyze when IOP 
decreased after surgery. Sometimes the repeatability of corneal measurements 
was poor. Unfortunately, measurements of the anterior chamber volume and angle 
were not reliable with Scheimpflug analyzer.
That we had no predetermined target IOP may have affected our results, 
especially concerning retrospective Studies I and IV. In these studies, follow-up 
was in part performed by local ophthalmologists, and the role of GP during the 
postoperative period was not fully realized, since many times medication was 
initiated before performance of GP. Sometimes the treating ophthalmologist 
may have been satisfied with the IOP lowering achieved by surgery, despite it not 
achieving a decrease of 25%. Performing GP was more controlled in prospective 
Studies II and III.
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2 THE EFFECT OF DS IN NTG (I, II, III)
DSCI reduces IOP efficiently even when target pressure is low. Its IOP-lowering 
effect is both clinically and statistically significant until 6 to 9 years postoperatively. 
In the prospective study, mean IOP after one year was 9 to 12 mmHg. This 
IOP-lowering effect was maintained during our follow-up with an IOP of 9 to 10 
mmHg after 6 to 9 years. 
Performing GP is mandatory for good IOP control postoperatively. The GP rate 
was almost 90% during our follow-up even with intraoperative MMC. Without 
MMC, all patients needed GP during our 6-to 9-year follow-up.
Trabeculectomy in NTG has been studied only in retrospective fashion. One 
recent study investigated the Moorfields Safe Surgery method with MMC in NTG 
with good results. IOP was lowered from 14.7 mmHg to 10.2 mmHg and IOP was 
>25% lower in 63.6% of eyes (Jayaram et al. 2016), with immediate postoperative 
hypotony in 2.3% and late hypotony in 0.8% of eyes. That study was retrospective, 
however, with only 24% of eyes, 31 out of 131, having a 4-year follow-up.
Another study reported good IOP-lowering results after traditional 
trabeculectomy with MMC: preoperative IOP of 13.3 mmHg decreased to 7.2 mmHg 
(Schultz et al. 2016). In their study, hypotony occurred in 20%, and hypotony 
maculopathy in 6% of eyes, and of 18 eyes, cataract surgery was needed for 8 (44%) 
during a follow-up of 4 years. That study was retrospective, and 50% of operated 
eyes had a 4-year follow-up. 
A third study with 39 eyes had a preoperative IOP of 15.9 mmHg and after 3 
years of follow-up, this was decreased to 12 mmHg (Jongsareejit et al. 2005), with 
hypotony maculopathy noticed in 18% of the eyes.
Postoperative IOP has been 7.2 to 12 mmHg after trabeculectomy with MMC 
in NTG patients after 3 to 4 years’ follow-up (Jongsareejit et al. 2005, Jayaram et 
al. 2016, Schultz et al. 2016). The IOP-lowering effect in our study after DS was 
similar: 9 to 10 mmHg after 6 to 9 years’ follow-up. 
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3 THE EFFECT OF DS IN POAG AND EXG (IV)
IOP can be significantly lowered with DS among POAG and EXG patients. This 
effect in IOP was apparent throughout our follow-up of 3 years. The preoperative 
IOP of 22.6 and 25.5 mmHg was lowered to 16.8 and 16.5 mmHg in the POAG 
and EXG groups at the last follow-up visit. Between POAG and EXG groups no 
difference emerged in postoperative IOP, but EXG patients needed more GP. 
Success rates showed no difference between EXG and POAG eyes.
My results are in concordance with previous findings (Drolsum 2006, Mendrinos 
et al. 2009, Ollikainen et al. 2011).
The largest prospective study had 37 EXG eyes operated on by DSCI with MMC. 
After 3 years, IOP was significantly reduced from 25 to 11 mmHg (Ollikainen et 
al. 2011). Complete or qualified success was achieved in 73% of eyes, with GP 
needed in 87%.
In another study of 22 eyes, the IOP-lowering result was of the same magnitude; 
preoperative 29.9 mmHg decreased to 13.2 mmHg 4 years postoperatively 
(Mendrinos et al. 2009). In their study, MMC was used in 23%, complete success 
was achieved in 54.5% and GP was performed in 63.6% of eyes.
A third study with 28 EXG eyes and 45 months’ follow-up showed good results 
as well concerning IOP lowering: preoperative 28.3 mmHg decreased to 15.5 mmHg 
after follow-up (Drolsum 2006). In that study, MMC was used in 18%, and GP 
was performed in 32%, with complete success for 50%.
The postoperative IOP achieved in my study of EXG was higher than in other 
studies (11 to 15.5 mmHg). That I analyzed the first consecutive eyes operated on 
with DS in our hospital, may have affected my results. MMC was used in only 
26.8% in EXG group, but today, MMC is used for a larger proportion. My success 
definition was an IOP between 4 and 17 mmHg, which was hard to achieve. My study 
was retrospective, and I had no target IOP determined before the operation. The 
follow-up of some of the patients was performed by private ophthalmologists who 
may have been satisfied with an IOP higher than 17 mmHg. The complete success 
rate in my study and in these other studies after 3 to 4 years’ follow-up has been 
from 43 to 54.5% (Drolsum 2006, Mendrinos et al. 2009, Ollikainen et al. 2011).
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4 THE EFFECT OF DS ON OCULAR  
 STRUCTURES (V)
I tried to find possible effect of DSCI on corneal topography, ocular dimensions 
and macular structures in a prospective study. Visual acuity decreased immediately 
after DSCI, but then increased back to preoperative level between two and 4 weeks 
postoperatively. Previously, even faster recovery of visual acuity after DS has been 
reported (Shaarawy et al. 2004).
AL decreased after DSCI, and this change persisted for up to 4 weeks 
postoperatively and was related to a decrease in IOP. Decrease in AL has occurred 
after trabeculectomy (Cashwell & Martin 1999, Karasheva et al. 2003, Usui et 
al. 2013). Our ACD was unchanged. Some amount of decrease in AL while ACD 
remains constant may be explained by changes in choroideal thickness. In one study 
of trabeculectomy, when IOP was lowered, AL decreased postoperatively (Saeedi 
et al. 2014). In their study, half the reduction in AL was explainable by thickening 
of the choroid. Unfortunately, when this study was made, I had no equipment to 
measure its thickness. Possible changes in choroideal thickness after DSCI would 
be an interesting study topic.
After DSCI, corneal dimensions showed changes. A steeper meridian of 
the cornea was further steepened one to 4 weeks postoperatively, and average 
corneal power increased one and 4 weeks postoperatively. The preoperative 
mean of steeper meridian is within 95% confidence intervals of postoperative 
measurements, indicating small actual change. Although differences in steeper 
meridian and average corneal power were statistically significant when compared 
to preoperative values, the amount of change was low, only 0.3D in steeper corneal 
curvature, and the clinical meaning of this change is doubtful. At the same time, 
spherical equivalence and subjective refraction remained unchanged, and 4 weeks 
postoperatively, visual acuity had already increased to preoperative level. The scleral 
flap was sutured loosely and did not affect the direction of corneal astigmatism.
Postoperatively, the central cornea became 6 to 7 um thinner. A similar 
finding has been made after trabeculectomy (Moschos et al. 2017). However, the 
preoperative mean thickness of central cornea is within 95% confidence intervals 
of postoperative measurements. Lowering IOP could theoretically alter endothelial 
function and lead to less fluid accumulating into the corneal stroma. An iatrogenic 
change in corneal structures can be achieved when creating a Descemet’s window; 
even detachment of the Descemet’s membrane with subsequent hemorrhage has 
been reported (Kozobolis et al. 2001).
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Normal diurnal variation of corneal measurements in my patients was unknown, 
and I had no control group in this study. In one study of glaucoma patients, up to 
12 um diurnal change in corneal thickness was measured (Villas-Boas et al. 2009). 
OCT analysis showed four patients having macular folds in association with 
hypotony 2 weeks postoperatively, and at 4 weeks, two of these persisted with 
good visual acuities. I found no signs of macular edema, and no change in macular 
volume or in foveal thickness. Macular edema has been found in 0 to 3.5% of eyes 
after DS (Dahan & Drusedau 2000, Bissig et al. 2008) and choroideal detachment 
in 0.5% to 7.6% (Bissig et al. 2008, Anand et al. 2011). My small sample size may 
explain why I found no signs of these adverse effects postoperatively. However, my 
findings support the view that after DS fewer changes in the ocular fundus occur 
postoperatively, compared to the situation after trabeculectomy (Cillino et al. 2004), 
and with DS, irreversible macular changes affecting visual acuity are uncommon.
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5 MITOMYCIN IN DS (I, II, III, IV)
In our prospective study, eyes having surgery with MMC had lower IOP until 
may have been diminished because of more frequent GPs and needlings in the 
non-MMC group. Moreover, the eyes in the non-MMC group also received MMC 
injections when needled. A larger study group with more power may have made 
to be small. We included all eligible NTG eyes in this prospective study for over 2 
years, between 2007 and 2009, at Helsinki University Central Hospital.
Eyes having surgery without MMC were more likely to need GP in the 
postoperative period, at 100% vs. 87%. Both of these groups had large amount of 
GP performed, but our follow-up period was as long as from 6 to 9 years. Rates 
















































It is therefore possible that when follow-up is continued until 10 years or longer, 
MMC eyes will also show a GP rate close to 100%.
A tendency toward more needling procedures appeared in our non-MMC group, 
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Adverse effects from MMC are sometimes feared since it is a potent agent 
affecting fibroblast activity. In our studies, MMC did not increase the number of 
adverse effects. After application, MMC was carefully washed away with balanced 
salt solution (BSS). Our method with MMC use is essentially the same as the 
Moorfields Safer Surgery technique (Dhingra & Khaw 2009). Polyvinylalcohol 
sponges soaked with MMC are inserted posteriorly under the conjunctiva to avoid 
contact with the limbal conjunctival margin. Sponges allow a constant amount of 
MMC to be released, and the contact time was 3 minutes. MMC was then carefully 
washed away with BSS. This method may allow a relatively standard amount of 
MMC to be in contact with ocular tissues.
MMC concentration was 0.4 mg/ml. Use of MMC with DS varies: good IOP 
control has been achieved without MMC in other glaucoma subtypes (Bissig et 
al. 2008), but many surgeons prefer MMC with DS at concentrations of 0.2 mg/
ml (Anand et al. 2011, Mansouri et al. 2011) to 0.4 mg/ml (Ollikainen et al. 2011). 
MMC at a concentration of 0.4 mg/ml has been used with trabeculectomy in NTG 
(Hagiwara et al. 2000, Jongsareejit et al. 2005, Shigeeda et al. 2002, Jayaram et 
al. 2016). Use of higher concentrations of MMC can be justified when treating 
NTG patients, since target IOP is low.
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6 PREDICTION OF SURGICAL OUTCOME AND   
 LEARNING-CURVE EFFECT
Success rates were better when IOP one week postoperatively was between 2 and 14 
mmHg in the Cox regression analysis of Study II. This finding is interesting, since 
postoperative follow-up could theoretically be adjusted accordingly. The reason 
for a too-high one-week IOP may be an incorrect dissection plane or a too-small 
filtration through the Descemet’s window. Later, these eyes may show a rise in IOP, 
when the scarring process lessens filtration. One-week IOP lower than 2 mmHg 
may be an indication of microperforation. In eyes with early microperforation of 
the Descemet’s window, a risk may occur for iris incarceration with subsequent 
problems in aqueous filtration. One-day IOP was found to be prognostic of 
postoperative IOP control in one study (Shaarawy et al. 2004), but another found it 
had no prognostic value (Guedes et al. 2011). Considering the results of my study, 
one-week IOP may have more prognostic value.
Previously it became clear that in viscocanalostomy, the effect of the learning 
curve is clear, with a better success rate achieved after the first ten cases (Jonescu-
Cuypers et al. 2001, Luke et al. 2002). In DS, achieving the correct dissection plane 
in the first cases has been difficult (Dietlein et al. 2000). We analyzed the effect 
of the learning curve on success rates with a Cox regression model, but in this 
small series, we failed to show any effect. This is in contrast to previous findings. 
My study consisted of first cases of POAG and EXG operated on with DS in our 
hospital. Today, MMC is more widely used, and GP is performed when IOP rises 
before initiation of topical glaucoma medication. Three eyes were reported having 
a perforation to the anterior chamber intraoperatively, and these were excluded 
from the study of 235 eyes. It is unlikely that excluding these affected my results 
concerning the learning curve effect.
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7 DS COMPLICATIONS
GP was common in our studies with longer follow-up (Studies III and IV), reaching 
87 to 100% in NTG patients after 6 to 9 years. Our results are in line with previous 
results (Figure 2). Target pressure in NTG patients is low, which may explain GP 
rates up to 100% with longer follow-up.
In EXG patients, GP was more common than in POAG patients. EXG eyes 
needed more GP than did POAG eyes, 81% vs 64%, but this may indicate that 
EXG is a more aggressive disease than is POAG, and IOP tends to increase more 
easily. Explanation may be that exfoliation material accumulates into, and possibly 
changes the function of, the trabecular meshwork (Morrison & Green 1988).
Another explanation may be the effect of exfoliation syndrome on the blood-
aqueous barrier, with possibly altered postoperative inflammation (Nguyen et al. 
1999). Another study had a similar result, with more GP performed on EXG (87%) 
than on POAG (61%) eyes during 3 years of follow-up (Ollikainen et al. 2011). In 
their study, all eyes were operated on in conjunction with MMC.
During GP, the non-penetrating DS procedure is essentially transformed to 
penetrating procedure, when the trabeculo-Descemet’s membrane is perforated 
with a YAG laser. Because of its high incidence after DS, GP is mainly considered 
an enhancement to a DS procedure rather than failure. After GP is performed, 
however, DS is no longer a non-penetrating procedure. 
GP is not free of risks. Its main complications are iris incarceration to the 
opening in the trabeculo-Descemet’s membrane and hypotony.
In Study III, iris incarceration to the Descemet’s window occurred, when groups 
were combined, in 32% of eyes, MMC use had no effect. Reported incidence of iris 
incarceration after GP has been 13.2% with 3 years’ follow-up (Anand & Pilling 
2010). In a more recent study, when Argon laser peripheral iridoplasty (ALPI) 
and laser iridotomy were performed on peripheral iris before GP (Di Matteo et 
al. 2016), iris incarceration rate was efficiently reduced to 3%. Risk of hypotony 
after GP has been 4% (Anand & Pilling 2010). Hypotony after GP has a high risk 
for development of hypotony maculopathy.
In POAG and EXG eyes, needling was required in 14 to 15%. The needling 
rate in these patients was as expected, as a needling rate of 14% has been usual 
in primary DS procedures (Anand et al. 2011).
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In NTG eyes with longer follow-up, needling was required for 13.5% of eyes 
rate in these NTG eyes was higher than in POAG or EXG. A possible explanation 
could be low target IOP in these eyes. In one study of DS after failed trabeculectomy, 
the needling rate was 32% after 5 years’ follow-up (Anand & Wechsler 2012), 
to continue for at least 6 years postoperatively after DS.
The need for a cataract operation was 4.0 to 7.7 %/ year after DS in our study 
and in others’ studies (Anand et al. 2011, Ollikainen et al. 2011). Cataract surgery 
is more common after trabeculectomy with an annual incidence of 10.1 - 11.0% 




































This can be clinically important, since besides transient loss of BCVA, the cataract 
In prospective studies II and III no combination procedures were included. In a 
lowering result was achieved, with a success (IOP <16 or 30% reduction, with or 
without medication) rate of 68.3% after three years’ follow-up (Mercieca et al. 2015).
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My prospective study (II) with NTG, had three eyes with hypotony (IOP <4 
mmHg) after 3 months, and two eyes after 6 months. All hypotonic eyes were 
in the MMC group. One of these eyes developed cystic maculopathy but was 
diagnosed as diabetic maculopathy with need of subsequent vitrectomy and anti-
vascular endothelial growth-factor injections. The non-MMC group had no cases 
of hypotony. After a follow-up of 6 to 9 years (Study III), one eye had an IOP of 
2 to 3 mmHg and one had 4 mmHg, both with visual acuities of 1.0 in Snellen.
In my retrospective study (IV) of EXG and POAG patients, no cases of hypotony 
were found. In these patients preoperative IOP was higher than in NTG patients, and 
MMC was used in only 30% of the eyes. No postoperative hypotony maculopathy 
was found. 
The incidence of hypotony has been 0 to 4% in other studies concerning DS 
with MMC (Cillino et al. 2008, Anand et al. 2011, Mesci et al. 2012). Incidence 
of hypotony maculopathy has been 0 to 3.5% (Dahan & Drusedau 2000, Bissig 
et al. 2008).
In our prospective studies, four eyes lost two or more lines in best corrected 
visual acuity (BCVA). Three of these were in the MMC group; one eye had cataract, 
one had macular degeneration, and one had diabetic maculopathy. In the non-





DS was safe and effective in reducing IOP in the one-year retrospective study. 
Nearly half of the eyes needed GP during the first postoperative year. Intraoperative 
complications consisted of tearing of conjunctiva and microperforation. 
Postoperatively, loss of BCVA was found but could be explained by cataract growth. 
Hypotony was common during the first postoperative week but diminished during 
the first month. No severe complications, such as endophthalmitis, blebitis or 
suprachoroidal hemorrhage were found.
(II)
In the prospective study DS reduced IOP effectively during the first postoperative 
year in both MMC and non-MMC groups. IOP was lower when MMC was used. 
However, in surgical success no benefit was found with MMC use. More than 
half of the eyes needed GP during first postoperative year. More hypotony was 
present during first three months when MMC was used, but none of the eyes was 
hypotonous one year postoperatively. MMC use was not related to other intra- or 
postoperative complications.
(III)
In the long-term IOP was effectively lowered throughout the 6 to 9 year follow-up. 
Postoperative IOP was lower in MMC group until 5 years postoperatively, thereafter 
no difference was found. In surgical success MMC use showed no additional benefit. 
Almost all eyes needed GP during follow-up. No difference between groups was 
found in postoperative complications or interventions.
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(IV)
In EXG and POAG eyes, DS reduced IOP effectively, with postoperative IOP being 
the same between groups. EXG eyes needed more reoperations. GP was more 
common among EXG eyes. IOP between 2 and 14 mmHg one week postoperatively 
was found to have prognostic value considering surgical success. No other factor 
with prognostic value for surgical success was found.
(V) 
Lowering IOP with DS resulted in a decrease of BCVA in the early postoperative 
period. BCVA returned to the preoperative level between 2 and 4 weeks 
postoperatively. Macular dimensions showed no change after DS. Two eyes 
had macular folds until 4 weeks postoperatively, but their visual acuities were 
unaffected. IOP lowering with DS shortened the eye as measured with an IOL-
master. Corneal curvature of steeper meridian increased and corneal thickness 
decreased after DS. These changes were relatively small, and these changes may 
not explain the lower visual acuity during first two postoperative weeks.
Several topics concerning DS remain to be resolved. It would be interesting to 
compare the effects and complications of DS and safe surgery trabeculectomy in a 
prospective and randomized study. Studying choroidal changes after DS could also 
be helpful in explaining changes observed in the immediate postoperative period. 
To find the effect of IOP lowering with DS on NTG patients concerning visual field 
deterioration would be important during a long follow-up of over 10 years. 
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